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Abstract 
 
Protein phosphorylation by cyclic AMP-dependent protein kinase (PKA) underlies key 
cellular processes including sympathetic stimulation of heart cells, and potentiation of 
synaptic strength in neurons. Unrestrained PKA activity is pathological, and an enduring 
challenge is to understand how the activity of PKA catalytic subunits is directed in cells. 
We developed a novel light-activated crosslinking approach to monitor PKA subunit 
interactions with temporal precision in living cells. This enabled us to refute the recently 
proposed theory that PKA catalytic subunits remain tethered to regulatory subunits 
during cAMP elevation. Instead, we have identified other features of PKA signaling for 
reducing catalytic subunit diffusion and increasing re-capture rate. Comprehensive 
quantitative immunoblotting of protein extracts from human embryonic kidney cells and 
rat organs reveals that regulatory subunits are always in large molar excess of catalytic 
subunits (average ~17-fold). In the majority of organs tested, type II regulatory (RII) 
subunits were found to be the predominant PKA subunit. We also examined the 
architecture of PKA complexes containing RII subunits using crosslinking coupled to 
mass spectrometry. Quantitative comparison of crosslinking within a complex of RIIβ 
and Cβ, with or without the prototypical anchoring protein AKAP18α, revealed that the 
dimerization and docking domain of RIIβ lies between its second cAMP-binding 
domains. This architecture is compatible with anchored RII subunits directing the 
myristylated N-terminus of catalytic subunits towards the membrane for release and re-
capture within the plane of the membrane. 
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Significance Statement 
 
Protein phosphorylation by cyclic AMP-dependent protein kinase (PKA) triggers cellular 
changes including fight-or-flight responses in heart cells, and synaptic potentiation in 
neurons. Uncontrolled activity of PKA catalytic subunits is pathological, however the 
mechanism for directing PKA in cells is unclear. Using a new approach for monitoring 
cellular PKA subunit interactions we show that - contrary to recent proposals - catalytic 
subunits are released from regulatory subunits by cAMP. Instead, we identify 
mechanisms for rapid re-capture of liberated catalytic subunits. Regulatory subunits are 
expressed much more highly than catalytic subunits to support rapid catalytic subunit re-
association. Furthermore, analysis of global PKA architecture reveals that type II 
regulatory subunit anchoring is compatible with catalytic subunit release and re-capture 
within the cell membrane. 
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\body 
 
Introduction 
cAMP-dependent protein kinase (PKA) is the major intracellular receptor for the second 
messenger cAMP (1). Activation of PKA by cAMP underlies responses throughout the 
body, including sympathetic regulation of the heart downstream of β-adrenergic receptor 
(β-AR) activation (2), and changes in the strength of synaptic connections between 
neurons (3). PKA consists of regulatory (R) subunit constitutive dimers that sequester 
catalytic (C) subunits prior to cAMP activation. There are two types of R subunit. Type II 
(RII) subunits associate with the low-speed particulate fraction after tissue 
homogenization, whereas RI subunits do not (4). This results from anchoring of RII, but 
generally not RI, at sub-cellular sites that include the cell membrane by A-kinase 
anchoring proteins (AKAPs) (2). Imbalances in the expression or activity of R (5) and C 
(6) subunits, or disruptions in PKA anchoring (7), lead to disease. An enduring challenge 
in cAMP/PKA research is to understand how PKA is directed to its cellular substrates. 
Experiments using fluorescent reporters have established that elevations in cAMP 
concentration and PKA activity are localized within the cell (8,	   9). However, these 
studies do not directly address how C subunits are restrained following their release. 
Following activation of an R-C complex by cAMP, the range over which the C 
subunit can phosphorylate substrates will depend on its rate of diffusion and the rate of 
re-capture by R subunits.  New potential mechanisms for reducing diffusion and 
increasing C subunit re-capture have been investigated in recent years. N-terminal 
myristylation is thought to restrict some free C subunits to the intracellular face of the 
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membrane bilayer (10), slowing their diffusion velocity (11) and restricting their activity 
to the plane of the membrane. Consistent with this model, RII but not RI subunits 
increase binding of myristylated C subunits to liposomes (12) probably by stabilizing the 
‘myr-out’ conformation of the myristylated C subunit A-helix (13, 14). Many AKAPs 
also localize to the cell and organellar membranes (15). AKAPs present amphipathic 
helices that bind to the dimerization and docking (D/D) domain formed by the first 45 
amino acids of RII subunits (16-18). However, the first 103 amino acids of RII are not 
visible in the electron density of the most complete crystal structures of RII-C (13, 19) so 
it is not clear whether association with membrane-tethered AKAPs is compatible with 
inserting C subunits into the membrane. 
An alternative proposed mechanism for limiting C subunit diffusion is that C 
subunits are never released from RII subunits but instead access nearby substrates while 
tethered to RII upon cAMP activation (20, 21). This theory was supported by 
experiments showing no effect of β-AR stimulation on C subunit co-precipitation with 
anchored RII subunits (20, 21). However, this experiment does not exclude the possibility 
that R and C subunits re-associate during co-immunoprecipitation following cell lysis. 
This possibility could not be excluded as, prior to our study, there has been no method to 
monitor association of endogenous PKA subunits in cells with temporal precision. Final 
aspects of PKA that could support rapid R and C subunit association are the 
stoichiometry and concentrations of its subunits. PKA is unusual among AGC protein 
kinases in that its regulatory and catalytic elements are formed by separate polypeptides 
(22). Binding studies show that increasing the concentration of RI subunits, with fixed C 
subunit concentration, increases the fraction of C subunits bound to R subunits even in 
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high concentrations of cAMP (23). This means that higher R subunit concentration 
increases the rate of R-C complex formation irrespective of cAMP concentration. 
Surprisingly, little information is available regarding the concentrations of endogenous 
PKA subunits. 
We used a three-pronged approach to investigate mechanisms for restraining C 
subunits. This combined approach has enabled us to more clearly define which 
mechanisms do – and do not - contribute to restraining C subunits. 
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RESULTS 
 
Light-activated crosslinking indicates that C subunits dissociate from R subunits in 
cells upon β-AR stimulation. To investigate the notion that C subunits remain tethered 
to R subunits in cells upon cAMP elevation (20, 21), we developed a novel approach that 
utilizes the UV light-activated crosslinker succinimidyl 4,4'-azipentanoate (SDA). We 
focused on human embryonic kidney (HEK) cells, which are a model cell line for 
studying cAMP/PKA signaling (24). An overview of this process is shown in figure 1A-C. 
Cells are first incubated with membrane-permeable SDA leading to covalent attachment 
at primary amines including lysine side-chains on RI (red, Fig. 1A), RII (blue) and C 
(green) subunits. During 365 nm illumination, the diazirine moiety of SDA may react 
with nearby molecules leading to covalent crosslinks (Fig. 1B). Since the SDA spacer 
arm is 3.9 Å, R-C crosslinking is strongly favoured when the two proteins are associated 
(Fig. 1B). After cell lysis, either RI subunits or RII subunits are precipitated using 
immobilized GST fusions (Fig. 1C) to the RI-selective sequence RIAD (25) or the C-
terminal 93 amino acids of RII-selective AKAP79 (AKAP79c93). R subunit precipitation 
is performed with cAMP so C subunit co-precipitation only occurs through R-C 
crosslinking. The efficacy of this approach is shown for HEK293T cells in figure 1D. 
GST alone precipitated neither RI nor RII (Fig. 1D, lanes 2 & 3) whereas GST-RIAD 
(lanes 4 & 5), and GST-AKAP79c93 (lanes 6 & 7) respectively pulled down either RI or 
RII. Control experiments confirmed that GST-RIAD pulls down RIα and RIβ with 
similar efficiency (Fig. S1A, B). UV exposure led to co-precipitation of covalently linked 
	   8	  
C subunits, visible as a band at 90 kD (Fig. 1D, IB:C) corresponding to either 1RI-1C 
(lane 5) or 1RII-1C (lane 7) crosslinked heterodimers. 
We applied this new approach to determine if RII and C subunits remain 
associated upon β-AR stimulation with isoproterenol. We incubated SDA-treated 
HEK293T cells for five minutes with either 1 μM isoproterenol or vehicle. UV light 
illumination was either performed immediately, or delayed until after cell lysis. Anti-C 
IB signal intensity at ~ 90 kD following RII subunit pull down shows how much C 
subunit was bound to RII at the moment of UV illumination (indicated by arrow, Fig. 1E). 
C-RII association was reduced following isoproterenol stimulation (Fig. 1E, lanes 2 & 3) 
by 78±7% (p = 0.0015, n = 4) according to densitometry (Fig. 1F, ‘pre-lysis’). On the 
other hand, C subunits were found to have returned to RII following lysis: when UV light 
illumination was delayed until post-lysis (Fig. 1E, lanes 4 & 5), isoproterenol led to a 
small increase in RII-C crosslinking (27±3%, p = 0.0016, n = 4, Fig. 1F). Re-association 
was abolished when we supplemented lysis buffer with 10 µM exogenous cAMP 10 min 
prior to UV-induced crosslinking post-lysis (Fig. S1C, D). We also performed 
experiments in which we coupled SDA crosslinking to GST-RIAD pull down. These 
experiments showed that C subunits also dissociate from RI upon isoproterenol 
stimulation (Fig. S1E-F). Together, our experiments using SDA crosslinking demonstrate 
that strong β-AR stimulation triggers C subunit dissociation from both RI and RII 
subunits in cells, and that co-precipitation of C in anti-RII immune complexes after 
isoproterenol stimulation (20, 21) likely occurs due to dilution of cAMP following cell 
lysis. 
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RI and RII subunits are in large excess of C subunits. The results of our SDA 
crosslinking experiments with live cells led us to consider alternative mechanisms for 
restricting C subunit activity. We next used quantitative immunoblotting to explore the 
possibility that R subunits outnumber C subunits.  We took advantage of highly specific 
antibodies, which we independently validated (Fig. S2), to detect RI, C, and either the α 
or β isoforms of RII subunits. Our approach is exemplified for analysis of homogenates 
extracted from HEK293T cells (Fig. 2). HEK293T cell extract was run alongside 
reference concentrations of highly purified C (Fig. 2A, top panel), RI (second from top), 
RIIα (second from bottom), or RIIβ (bottom panel). Antibody binding was determined 
using a chemiluminescent substrate in tandem with a charge-coupled device imager, and 
intensity at reference subunit concentrations was used to fit Hill function calibration 
curves for C (Fig. 2B, top left panel), RI (top right), RIIα (bottom left), and RIIβ (bottom 
right). All protein extracts were quantified using this approach (Fig. 2B and Fig. S3). In 
the case of HEK293T cells, it was possible to approximate subunit copy numbers per cell 
(Fig. 2C, Table S1). Numbers from four independent sets of experiments revealed that 
there are approximately 2.42±0.21x105 C, 7.34±0.13x105 RI, 15.4±0.23x105 RIIα, and 
3.00±0.69x105 RIIβ subunits per cell (Fig. 2C, Table S1). These copy numbers are the 
same order of magnitude as the GTPase Ras (26), another wide-acting signaling protein. 
HEK293 cell volume has been determined by different methods (27, 28) to be ~2 pL/cell. 
This equates to cellular PKA subunit concentrations of ~ 1.5 μM for RII, ~ 0.6 μM for RI, 
and ~ 0.2 μM for C subunits. 
To investigate whether this uneven subunit ratio is a general feature of PKA 
signaling, we analyzed protein extracts collected from Sprague-Dawley rats. Brain tissue 
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was extracted and separated into forebrain and cerebellum, and a fraction enriched in 
nerve endings was also collected from forebrain. Additional extracts were prepared from 
heart, liver, lungs, and skeletal muscle. An identical protein extraction method was used 
in all cases. In sum, subunit concentrations were determined in protein extracts from 
eight different sample types (Fig. S3). Average concentrations (n=4) are shown in ng/mg 
protein extract in figure 3A. PKA subunit concentrations are relatively high in forebrain, 
with RIIβ accounting for 0.29 % total forebrain protein; and combined forebrain PKA 
subunits constitute 0.41 % forebrain protein (Fig. 3A).  These concentrations are 
approaching those of calmodulin-dependent protein kinase II, which constitutes 0.86 % 
cerebral cortex (29), and calcineurin which is ~1 % of cerebral cortical  and hippocampal 
protein (30). 
We next calculated copy numbers of RI (red, Fig. 3B), RIIα (light blue), and RIIβ 
(dark blue) relative to C subunits (green) in each extract type. In all cases, R subunits 
greatly outnumber C subunits with a combined average of 17.2±1.7-fold more R than C 
subunits (p = 4.8x10-6, Fig. 3B). To our knowledge, this is the first concrete 
demonstration of this fundamental aspect of cAMP signaling. When the average copy 
numbers are compared by student’s t-test in each extract, both RI and RII separately 
outnumber C subunits with p < 0.05 in every case except RI in liver in which the 
comparison is under-powered (p = 0.051). R subunits are in greater than 20-fold excess 
of C subunits in forebrain, cerebellum and lungs. A combined analysis of all ratios 
reveals that RII subunits typically outnumber RI subunits by ~2:1. Cerebellum and heart 
are notable exceptions to this rule. The ~2-fold higher expression of RI than RII in 
cerebellum may be related to the different (presynaptic) role that PKA plays in synaptic 
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plasticity in cerebellar granule cells (31, 32). The elevated expression of the β isoform of 
RII in brain extracts is consistent with previous reports (33). Overall, our stoichiometric 
analysis reveals that C subunits are greatly outnumbered by R subunits across tissue types. 
 
Insights into anchored type II PKA holoenzyme structure from crosslinking coupled 
to mass spectrometry (XL-MS). We next aimed to resolve uncertainties in the structure 
of anchored RII-C complexes in an effort to determine whether anchoring of RII subunits 
– the predominant R subunit isoform in most organs (Fig. 3B) – is compatible with 
release and capture of C subunits in the cell membrane. There are two conceivable 
positions for the D/D domain within the RIIβ-C complex: between the N-lobes of the C 
subunits, or between the second cyclic nucleotide binding (CNBB) domains of the RII 
subunits (13, 19). To resolve this uncertainty, we turned to XL-MS, which is a rapidly 
developing technique suited to structural investigation of large dynamic multi-protein 
complexes (34). In XL-MS, protein samples are crossslinked, digested into peptides, and 
the sequence of crosslinked peptides is determined by MS. Crosslinks reveal which 
regions of the protein complex are close in space. We utilized the homobifunctional 
crosslinker disuccinimidyl suberate (DSS), which links amines including those at the 
termini of lysine side-chains with a maximum span of ~ 30 Å (34). We first crosslinked 
PKA holoenzymes comprising RIIβ-Cβ, either alone or in complex with AKAP18α. 
AKAP18α possesses typical AKAP properties that make it a suitable prototype for 
studying PKA structure (18, 35) including lipid modification sites in its first six amino 
acids that enable membrane insertion (36). Samples were imaged using Coomassie 
staining, immunoblotting and RII overlay following electrophoresis either before (odd 
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number lanes, Fig. 4A) or after (even lanes, Fig. 4A) DSS incubation. Crosslinking of 
RIIβ-Cβ led to prominent bands at ~90 and 140 kD, with a weaker band at ~180 kD. 
Anti-C (lane 6, Fig. 4A), and anti-RIIβ (lane 10) immunoblots (IBs) indicate that these 
three species represent 2RII, 2RII-1C, and 2RII-2C. Inclusion of the AKAP shifts all 
three bands higher (first three panels, Fig. 4A) by approximately the mass of AKAP18α. 
RII overlay confirmed that AKAP18α was effectively crosslinked within the complex 
(lane 16, Fig. 4A). Sequences of crosslinked peptides identified in the RIIβ-Cβ and 
AKAP18α-RIIβ-Cβ samples are listed in Tables S2 and S3, respectively. A total of 126 
crosslinked peptides were identified following crosslinking of RIIβ-Cβ, including 42 R-R 
intralinks, 74 C-C intralinks, and 10 R-C interlinks. Figure 4B shows the overall pattern 
of intralinks (purple), and interlinks (black) after crosslinking RIIβ (blue) and Cβ (green) 
in the absence of AKAP18α. 
Nine different types of crosslink were identified linking RIIβ K46 at the C-
terminus of the D/D domain to lysines visible in crystal structures of RIIβ-C (14, 37). In 
six cases, RIIβ K46 is coupled to sites in CNBB (positions 263, 266, 276, 326, 328, & 
357), with a further partner lysine (Cβ K285) that projects over CNBB (Fig. 4C). This 
pattern of crosslinking is consistent with the D/D domain lying between the CNBB 
domains of the RIIβ dimer. XL-MS with purified RIIβ-Cβ-AKAP18α led to 
identification of two interlinks involving AKAP18α (Table S3): AKAP18α K19 linked to 
Cβ K285, and AKAP18α K65 linked to RIIβ K263. AKAP18α K19 lies between the N-
terminal lipid attachment sites and the R subunit anchoring helix of the AKAP (positions 
27-42), whereas K65 lies near to the C-terminus of the anchoring protein. These 
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interlinks are consistent with AKAP18α docking to a D/D located between the CNBB 
domains of the RII dimer (Fig. 4C). We also analyzed a complex of RIIα and Cβ using 
XL-MS (Fig. S4A, Table S4). This analysis was less powerful as the only reference lysine 
within the first 100 amino acids of RIIα (K71) is mid-way between the autoinhibitory 
sequence and D/D domain (Fig. S4B). Furthermore, there are no crystal structures of 
tetrameric RIIα-Cβ for reference. Nevertheless, the pattern of interlinks between RIIα 
K71 and Cβ (Fig. S4C) is consistent with the D/D adopting a similar position relative to 
the C subunit in both RII isoforms. 
 
Quantitative XL-MS (q-XL-MS) confirms the position of the RIIβ D/D. We next 
quantified how addition of AKAP18α altered the abundance of crosslinks within RIIβ-
Cβ. We anticipated that dynamic links would help to establish where the AKAP binds 
and if it alters the conformation of RIIβ-Cβ. We used the xTract algorithm (38) to 
identify changes in the abundance of 45 unique crosslinked sites that we were able to 
reliably quantify over the different replicate samples (Table S5). Five crosslinking sites 
decreased to less than half their original abundance upon addition of AKAP18α (Table 1, 
red links in Fig. 4D). The greatest decrease was observed for a link between RIIβ lysines 
285 and 333 (5.4-fold decrease, p = 1.32 x 10-9, Fig. 4D). The four other decreasing links 
involved conjugation of RIIβ K46 to lysines either within (RIIβ lysines 263, 285 & 357) 
or adjacent to (Cβ K266) RIIβ CNBB (red, Fig. 4D). This pattern of down-regulated 
links confirms that the D/D domain of RIIβ lies between its CNBB domains: binding of 
AKAP18α to the D/D domain sterically impedes DSS from bridging between lysines in 
this region of PKA (Fig. 4D). Surprisingly, three crosslinks were increased by more than 
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50 % (p < 0.01) upon addition of AKAP18α (Table 1, purple, Fig. 4E). All three links 
fall within the C subunit N-lobe, suggesting that binding of AKAP18α propagates a 
structural rearrangement in this region that enables DSS to crosslink some N-lobe lysines 
more efficiently. Two of the upregulated links involve lysines within the C subunit A-
helix (lysines 16 and 21, Fig. 4E), which is a locus for post-translational modification 
including myristylation. The N-terminus of AKAP18α, which is separated by ~20 amino 
acids from the anchoring helix, is also lipidated at three sites for insertion into the cell 
membrane. RII subunits, anchored to this AKAP at least, are therefore likely to orient C 
subunits with the myristylated A-helices pointing towards the cell membrane (Fig. 5). 
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DISCUSSION 
This study presents three sets of experiments that clarify how PKA C subunits are 
controlled in cells. First, experiments using SDA demonstrate that C subunits are released 
from both RI and RII upon cAMP elevation, suggesting that tethering to R subunits 
during cAMP activation does not constitute a cellular mechanism for restricting C subunit 
activity. This is consistent with many in vitro measurements showing cAMP-induced R-C 
subunit dissociation using methods including scintillation proximity assay and surface 
plasmon resonance (23, 39), and with FRET changes between microinjected and 
genetically-encoded R and C subunits bearing fluorescent labels (40, 41). Second, subunit 
quantitation in a range of protein extracts reveals that R subunits typically exist in a ~17-
fold excess of C subunits, with very high concentrations in tissues including forebrain. 
High subunit concentrations, and ratios heavily skewed towards R subunits, will support 
high rates of R-C association in cells, thereby limiting the distance from point of release 
over which C subunits can phosphorylate substrates. Typically, membrane-associated RII 
subunits outnumber RI subunits by ~2 to 1. XL-MS analysis of PKA tetramers containing 
RII subunits (Fig. 5 and Fig. S4) suggests that in general anchored type II isozymes orient 
with the N-terminus of the C subunit pointing towards the anchoring site. In the case of 
AKAP18α-RIIβ-Cβ, this architecture suggests that myristate (yellow, Fig. 5) and 
palmitate (pink) groups attached at the N-termini of AKAP18α (black) and the C subunit 
(green) could simultaneously insert into the cell membrane in type IIβ holoenzymes 
anchored to this AKAP.  
We found that PKA subunit concentrations and ratios vary with tissue type (Fig. 
3B). The four PKA R subunit isoforms are structurally and functionally different. Studies 
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with genetically modified mice (42) suggest that RIIβ is more functionally critical than 
RIIα. Type IIβ tetramers are also more compact (1) and less sensitive to cAMP (37) 
compared to RIIα. We found that RIIβ subunits are the predominant PKA subunit in 
forebrain, whereas RIIα subunits predominate in lungs and skeletal muscle (Fig. 3B). It 
should be noted that within the forebrain, RIIα and RIIβ exhibit marked neuron-specific 
patterns of expression (43). Genetic studies suggest that RI is more important than RII for 
regulating nuclear C subunit entry and concomitant gene expression (1, 23, 43). We 
found that RI subunits outnumber RII subunits in only heart and cerebellar extracts (Fig. 
3B). Cardiac myxoma is a common symptom of Carney complex (CNC), which is caused 
in most cases by inactivation of the gene coding for RIα (5, 44). This is consistent with a 
prominent role for RI subunits in inhibiting cardiac C subunits. Anchored type II PKA 
isozymes are thought to be responsible for rapid PKA signalling processes, including ion 
channel regulation (15). Consistent with this model, we found very high expression levels 
of RII subunits in forebrain. Our XL-MS measurements show that anchoring of RIIβ, and 
potentially RIIα, subunits is compatible with membrane insertion of C subunits within 
anchored type II tetramers. Substrate concentration affects the cAMP sensitivity of type I 
– but not type II - PKA holoenzymes (45). The insensitivity of RII subunits to substrate 
concentration may support rapid C subunit binding and release within the plane of 
neuronal membranes where local substrate concentrations are high. Membrane tethering 
of C subunits released from RII subunits could potentially explain why nuclear C subunit 
activity is more dependent on RI subunits (23, 43). Consistent with this model, binding of 
C subunits to RII but not RI favours the myr-out conformation that enables efficient C 
subunit membrane insertion (12). A-kinase interacting protein 1 (AKIP1) and protein 
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kinase inhibitor peptide (PKI) will also influence the cellular localization of C subunits. 
AKIP1 is nuclear (46) and binds to the N-terminus of the PKA C subunit, whereas the 
nuclear localization of PKI is cell cycle-dependent (47). PKI could potentially inhibit ≥ 
20 % C in some neurons but there is uncertainty regarding its exact concentration in brain 
extracts (47) so it is difficult to relate our calculated concentrations for R and C subunits 
to PKI. 
In vitro binding studies have previously shown that the fraction of 30 nM Cα 
bound to RIα rises with increasing [RIα], in the presence of 50 μM cAMP, with Kd = 
0.24 μM (23). Our estimates for PKA subunit concentrations in HEK293T cells (2 μM 
RII, 0.7 μM RI, and 0.2 μM C) show that PKA subunits are present at substantially 
higher concentrations than this Kd in cells. Consistent with a prediction by Kopperud and 
co-workers (23) that a minority of C subunits remain associated with R subunits during 
maximal cAMP elevation in cells, we detected residual RI-C/RII-C crosslinking upon 
strong β-AR stimulation at ~16/22 % of the basal crosslinking intensity according to 
semi-quantitative densitometry (Fig. 1E and Fig. S1E). In comparison, addition of 
exogenous 10 μM cAMP to post-lysis material led to a more pronounced reduction in 
RII-C crosslinking to ~4 % of the level without cAMP (Fig. S1C-D). Therefore, the 
residual R-C crosslinking observed in cells probably represents partial R-C association 
during strong β-AR stimulation of HEK293T cells. Together, our subunit quantitation 
and SDA measurements suggest that abundant R subunits support high rates of R-C 
association such that even maximal β-AR stimulation does not fully dissociate R and C 
subunits.  
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The phosphorylation state of RII subunits is also emerging as an important 
determinant of the rate at which C subunits bind to RII subunits (14). A recent study 
quantified kon constants for C subunit binding to RIIα using surface plasmon resonance 
(14). Remarkably, dephosphorylation of RIIα Ser112 increased the kon coefficient for C 
subunit binding by 60-fold (14). We detected molar excesses of RII subunits relative to C 
subunits in every rat extract tested (Fig. 3B). Therefore, typically the autoinhibitory 
sequences of most RII subunits will be unencumbered by C subunits and accessible to 
cellular phosphatases. Phosphatase access is not relevant to RI since the autoinhibition 
sequence of these regulatory subunits contains an alanine at the equivalent position to 
Ser112 (1). A recent study showed that U2OS cells expressing a fusion of RIIα and Cα 
subunits (‘R2C2’), in place of endogenous Cα and RII subunits, exhibit PKA activity 
according to a cytoplasmic AKAR4 reporter following isoproterenol stimulation (21). 
Nuclear AKAR4 responses are blunted in cells expressing the R2C2 fusion (21). A 
possible explanation for these findings is that residues corresponding to the C subunit are 
still able to sufficiently dissociate from the regulatory elements of RII within the context 
of the fused R2C2 polypeptide to phosphorylate AKAR4 in the cytosol. An analogy 
would be activation of other AGC protein kinases by dissociation of regulatory and 
catalytic elements within a single polypeptide, such as in activation of protein kinase G 
(22). The artificially high (equimolar) ratio of C to RII, and potentially raised RII 
phosphorylation, in R2C2 may counterbalance reductions in cAMP-induced dissociation 
due to fusing the two subunits within a single polypeptide. Since the C subunit cannot 
diffuse away from RII after dissociation in the context of R2C2, it will be unable to pass 
into the nucleus, consistent with blunted nuclear AKAR4 responses in cells expressing 
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R2C2 (21). Nevertheless these experiments suggest that, at least in the cytosol, PKA 
phosphorylation can be achieved with diffusion of the C subunit over a very short 
distance from RII. 
Rapid fluctuations in local cAMP concentration, supported by co-localization of 
PKA with adenylyl cyclases and phosphodiesterases, will also support faster release and 
binding of C subunits to R subunits. For example, type IV PDEs can anchor to AKAPs 
(48), and direct PKA-PDE coupling has been detected (49). XL-MS is developing rapidly, 
and it is plausible that the technique could be applied to study cAMP signaling complexes 
in cells. In future, it will be exciting to determine how anchored PKA complexes are 
oriented in relation to interaction partners including cyclases, phosphodiesterases and 
receptors (50). 
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Materials & Methods. For quantitative immunoblotting, samples were collected from 
HEK293Ts and male, four-week-old, Sprague-Dawley rats and homogenized using a DI 
25 Basic rotor/stator homogenizer (Yellowline) and 20 KHz sonication. Experiments 
involving rats were done in accordance with the UK Animals Act, 1986, and with UCL 
Animal Research guidelines. For XL-MS measurements, digested PKA complexes were 
analyzed on Orbitrap Elite and Fusion Tribrid mass spectrometers (Thermo). For qXL-
MS analysis, we compared the intensities of peaks eluting for crosslinks between the 
RIIβ-Cβ and RIIβ-Cβ-AKAP18α samples using xTract (38). Results are presented 
throughout as mean ± sem. Data were analysed by two-sided Student’s t-test. p values are 
*p<0.05, **p<0.01, ***p<0.001. Detailed methods can be found in SI Materials and 
Methods. 
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Figure Legends 
 
Figure 1. Light-activated crosslinking of PKA subunits in HEK293T cells. (A) SDA 
covalently binds to free amine groups through its NHS moiety, including to lysines 
presented by RI (red), RII (blue) and C (green) subunits. (B) UV light triggers 
crosslinking between associated subunits. (C) Following lysis, isoform-selective R 
subunit pull down is performed with immobilized GST fusions. (D) R subunit pull down 
was performed with control GST, GST-RIAD, or GST-AKAP79c93. R-C heterodimer 
precipitation (marked by arrow) required both R subunit pull-down and UV light 
exposure. (E) SDA-treated HEK293Ts were incubated with vehicle or 1 μM 
isoproterenol. Cells were then either immediately exposed to UV light (‘pre-lysis’), or 
exposure was delayed until post lysis. RII subunits were selectively pulled down in all 
cases. (F) Densitometry showing that isoproterenol reduced RII-C crosslinking in live 
cells (‘pre-lysis’). RII-C crosslinking was slightly increased by isoproterenol (n=4) when 
UV exposure was delayed until after lysis. ***p<0.001. 
 
Figure 2. PKA subunit stoichiometry in HEK293T cells (A) Subunit-selective IBs for 
PKA subunit quantitation in HEK293T cell extract. Reference concentrations of purified 
Cβ, RIβ, RIIα or RIIβ were run alongside HEK293T cell extract. In the example shown, 
the amount of extract loaded per lane varied depending on the IB as follows (μg total 
protein): 32.3 (Pan C), 33.3 (Pan RI), 26.0 (RIIα), and 35.4 (RIIβ). (B) Calibration curves 
derived from reference protein intensities in panel A. According to the reference curves, 
the respective HEK293T extract lanes contained (ng subunit): 1.54 (Pan C), 4.61 (Pan RI), 
12.6 (RIIα), and 2.29 (RIIβ).  (C) Subunit copy numbers per HEK293T cell (n=4)  
 
Figure 3. PKA subunit quantitation in panel of protein extracts. (A) Average subunit 
concentrations (n=4) are shown at ng/mg total extracted protein. Protein concentration is 
indicated according to the heat bar on the right. (B) Relative copy numbers of RI (red), 
RIIα (light blue), and RIIβ (dark blue) subunits are shown relative to C subunits (green). 
Numbers were determined from quantitation of extracts from four rats.*p<0.05, **p<0.01, 
***p<0.001. 
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Figure 4. Structural insights into type IIβ PKA anchoring from XL-MS. (A) The first 
two lanes of each sub-panel correspond to mixtures of PKA Cβ and RIIβ; the latter two 
lanes correspond to AKAP18α-Cβ-RIIβ. Samples in even numbered lanes were subjected 
to DSS crosslinking prior to electrophoresis. The samples were visualized by Coomassie 
staining (5 μg sample/lane), anti-C IB (1.67 ng in lanes 5 & 7; 83 ng in lanes 6 & 8), anti-
RIIβ IB (50 ng/lane), or by far-western blotting with PKA RIIα subunits (40 ng/lane). 
DSS crosslinking interfered with anti-C subunit antibody recognition so it was necessary 
to load 50-fold more material in lanes 6 & 8 than 5 & 7. (B) Distribution of intralinks 
(purple) and interlinks (black) within Cβ-RIIβ. Panels (C) to (E) were assembled using 
PDB IDs 3TNP (37) and 4ZP3 (18) with proteins colored black (AKAP18α), green (C) 
and blue (RIIβ) and lysine carbon-α atoms represented as spheres. (C) Location of 
interlinks detected between AKAP18α and Cβ –RIIβ. (D) Pattern of Cβ –RIIβ crosslinks 
(red) reduced by inclusion of AKAP18α. (E) Location of three intralinks (purple) within 
Cβ that were increased by AKAP18α addition. 
 
Figure 5. Updated model of AKAP18α-RIIβ-Cβ complex. Proposed orientation of 
RIIβ (blue) dimer with associated Cβ (green) in relation to its AKAP18α (black) 
anchoring site and the cell membrane (grey). The location of the D/D domain, as 
determined from XL-MS data, suggests that myristate (yellow) and palmitate (pink) 
groups attached to AKAP18α and Cβ point in the same direction supporting membrane 
insertion of Cβ. 
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SUPPLEMENTARY INFORMATION for: 
Mechanisms for restraining cAMP-dependent protein kinase revealed by subunit 
quantitation and novel crosslinking approaches 
 
 
EXTENDED MATERIALS AND METHODS 
 
Light-activated crosslinking in HEK293T cells 
HEK293T cells were cultured as described in Preparation of protein extracts. At 80% 
confluence, cells were resuspended in DMEM from plates totalling 350 cm2, and pelleted 
by centrifugation at 1,200 x g for 4 min at room temperature (RT). The cells were washed 
by resuspending in 10 mL PBS, and pelleted again by centrifugation for 4 min at 1,200 x 
g. 10 mM SDA (Thermo Fisher Scientific) was freshly prepared at 10 mM in DMSO. 1 
mL of SDA stock was added to 9 mL PBS for a final concentration of 1 mM. This 
solution was used to resuspend the pelleted HEK293T cells. The cell suspension was 
incubated at 22 °C with 1 mM SDA on a roller mixer for 30 min, after which 1 M Tris 
pH 7.4 was added to a final concentration of 10 mM to quench unreacted NHS moieties.  
The cells were pelleted as before, the supernatant was aspirated, and the cells were 
washed with 10 mL PBS. The cells were next resuspended in 10 mL PBS supplemented 
with 1 μM isoproterenol if appropriate.  Isoproterenol hydrochloride was prepared 
immediately prior to experiments by dissolving in PBS to produce 1 mM stock solutions. 
Following 5 min incubation at 22 °C, cells were next transferred to a 60 cm2 tissue 
culture dish and illuminated on ice with UV light from a high-intensity Blak-Ray B-
100AP 365 nm UV lamp (UVP) positioned ~ 10 cm above the surface of the plate.  After 
illumination for 5 min, cells were pelleted as before, the supernatant was aspirated, and 
the cells were washed in PBS and pelleted once more. The cells were resuspended in 1 
mL extraction buffer, sonicated and centrifuged at 21,100 x g for 1 h at 4 °C.  The 
supernatant was collected for R subunit-selective pull down. For ‘post-lysis’ UV-induced 
crosslinking, UV-induced crosslinking was delayed until after cell lysis. In these cases, 
the supernatant was collected and incubated overnight at 4 °C on a rotating mixer.  On 
the following morning, the sample was diluted into 9 mL detergent-free extraction buffer 
	   2	  
then subjected to 5 min UV illumination as above. Post-lysis UV illumination samples 
were supplemented with 10 µM cAMP 10 min prior to UV illumination as appropriate. 
 
R subunit-selective pull-down 
On mornings in advance of HEK293T SDA crosslinking later in the day, 30 μL aliquots 
of Glutathione Sepharose 4 Fast Flow beads (GE Healthcare Life Sciences) were charged 
with 30 µg GST, GST-RIAD, or GST-AKAP79c93. In each case, bead charging was 
performed by incubating on a rotating mixer at 4 °C for 2 h in 500 μL pull-down buffer 
(20 mM HEPES pH 7.5, 200 mM NaCl, 2 mM DTT, 1 mM EDTA, 0.05% TWEEN 20).  
The beads were washed with 4 x 1 mL pull-down buffer, then transferred to 15 mL falcon 
tubes in a final volume of 4.5 mL of the same buffer. 1 mL HEK293T cell extracts were 
divided into two, and 0.5 mL lysate was added to the appropriate charged beads (typically 
half to GST-RIAD, and half to GST-AKAP79c93 beads). The mixtures were incubated 
overnight on a rolling mixer at 4°C.  On the following morning, beads were pelleted at 
1,200 x g for 3 min, and the supernatant was aspirated.  The beads were washed with 5 x 
1 mL pull-down buffer supplemented with 1 mM cAMP to remove C subunits non-
covalently bound to R subunits. After the final wash step, the beads were resuspended in 
1 x NuPAGE LDS Sample Buffer (Thermo Fisher Scientific) supplemented with 10 mM 
DTT, and incubated at 85 °C for 10 min to release GST fusion and associated proteins. 
Covalent attachment of C subunits to RI or RII was assessed by immunoblotting using 
anti-Pan C antibody. Densitometry was performed in the linear range of the antibody 
when performing quantitative comparisons. 
To test if GST-RIAD is capable of pulling down both RIα and RIβ, 20 μL 
aliquots of glutathione sepharose beads, charged with 12 μg GST-RIAD, were incubated 
with 1 mL extraction buffer containing 0.11 ng/μL of either RIα or RIβ. After overnight 
incubation at 4 °C on a spinning mixer, the beads were washed with 5 x 200 μL 
extraction buffer, and protein was released from the glutathione sepharose as above.  
Pulldown efficiency was assessed by anti-Pan RI antibody IB. 
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Protein expression and purification 
All PKA subunits purified during this investigation correspond to the human sequences. 
RII lysines are numbered according to the equivalent positions in crystallized mouse 
sequences to facilitate cross-referencing with crystal structures (2QVS for RIIα, 3TNP 
for RIIβ). PKA Cβ, RIα, RIβ, RIIα, RIIβ, AKAP18α, AKAP79 (335-427), and RIAD 
were expressed as PreScission-cleavable fusions at the C-terminus of GST using the 
vector pGEX6P1.  PKA Cα was expressed with an N-terminal 6xHis tag using pET28a. 
All proteins were expressed in E. coli BL21 (DE3) cells by inducing cultures of 1.6-4.8 L 
at an OD600nm ~ 0.7 with 375 μM IPTG.  Following incubation with shaking at 20 °C 
overnight, cells were pelleted by centrifugation for 10 min at 4,000 x g.  Cell pellets were 
washed in PBS, and frozen at -80°C prior to processing. All protein purification steps 
were performed on ice. For cell lysis, cell pellets were thawed in 50-100 mL of either 
glutathione sepharose binding buffer (30 mM HEPES pH 7.5, 500 mM NaCl, 2 mM DTT, 
0.5 mM EDTA, and 1 mM benzamidine) or Ni-NTA binding buffer (30 mM Tris pH 8.0, 
500 mM NaCl, 10 mM Imidazole, 1 mM benzamidine) as appropriate. All lysates were 
supplemented with 0.1 µg/mL lysozyme; lysates for purifying AKAP18α, Cβ, RIIβ, RIα 
were supplemented with 10 % glycerol; the AKAP18α lysate was supplemented with 
0.5 % Triton TX-100; and the Cα lysate was supplemented with one Complete EDTA-
free protease inhibitor tablet (Roche) per 100 mL lysate. Lysates were sonicated at 20 
kHz for 2 x 30 s then mixed on a roller for 30 min prior to centrifucation at 31,360 x g for 
30 min.  Clarified supernatants were incubated for either 3 h with 2 mL Glutathione 
Sepharose 4B (GE Healthcare Life Sciences) or 1 h with 2 mL Ni-NTA agarose (Qiagen) 
as appropriate.  Following binding, affinity beads were washed with 3 x 10 mL binding 
buffer prior to elution. 
 Elution from glutathione sepharose was performed in two ways depending on 
whether cleavage from GST was desired. For GST fusion proteins, elution was performed 
by incubating for 1 h with 2 mL of binding buffer supplemented with 10 mM L-
glutathione. For release of purified PKA subunit alone, beads were incubated with 60 μg 
PreScission protease (GE Healthcare Life Sciences) in 2 mL glutathione sepharose 
binding buffer.  In this case, elution was performed by overnight incubation at 4°C. 
Elution of His-tagged Cα subunits from Ni-NTA agarose was performed in batch by 
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incubating with Ni-NTA elution buffer (30 mM Tris pH 7.0, 500 mM NaCl, 300 mM 
imidazole, 1 mM benzamidine). In the final purification step, all protein samples were 
separated by size exclusion chromatography (SEC) using an 80 mL Superdex 200 column 
(GE Healthcare Life Sciences) controlled by an ÄKTA fast protein liquid 
chromatography system (GE Healthcare Life Sciences). SEC was performed with 
HEPES-NaCl buffer (20 mM HEPES pH 7.5, 200 mM NaCl). High purity protein was 
collected from peak fractions on the basis of Coomassie staining fractions separated by 
gel electrophoresis on 4-12 % Bis-Tris NuPAGE gels (Thermo Fisher Scientific). 
 
Preparation of protein extracts 
Male, four-week-old, Sprague-Dawley rats were euthanized by cervical dislocation, and 
organs were removed immediately. Forebrain, cerebellum, heart, tibialis anterior muscle, 
lung, and liver were excized on ice, washed in phosphate-buffered saline (PBS), and 
weighed. Extraction buffer (30 mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 1 
mM benzamidine, 1% (w/v) Igepal CA-630, and 0.25% (w/v) sodium deoxycholate) was 
added to each sample at 1 mL per 100 mg wet mass. The organs were manually sliced 
into smaller pieces before homogenization at 9,500 rpm using a Di 25 basic rotor/stator 
homogenizer (Yellowline) for 2 x 30 s. The homogenate was next sonicated for 30 s at 20 
KHz and finally clarified by centrifugation at 21,130 x g for 1 h at 4 °C.  The resulting 
supernatant was collected for quantitative immunoblotting and measurement of total 
protein content using bicinchoninic acid (BCA) assay. The concentration of protein in 
extracts was determined by BCA assay (mg/mL): cerebellum (6.68±0.70), forebrain 
(8.52±0.25), heart (7.73±0.71), liver (13.50±1.38), lung (8.21±1.15), skeletal muscle 
(5.71±0.48), and nerve-ending rich forebrain fraction (8.83±0.48). Nerve ending-enriched 
fractions were collected using Dounce homogenization to fraction ‘S1’.  Briefly, rat 
forebrains were excized, rinsed in ice cold sucrose/EDTA buffer (0.32 M sucrose, 1 mM 
EDTA, 5 mM HEPES pH 7.4), weighed, and resuspended in 3.5 mL sucrose/EDTA 
buffer. After coarse manual chopping, the sample was processed using a Dounce 
homogenizer (5 strokes with loose insert followed by 5 strokes with tight insert). The 
homogenate was centrifuged at 1,000 x g for 10 min, and the resulting supernatant was 
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collected for analysis. BCA assay indicated that this protocol yields ~ 30 mg protein per g 
starting wet mass. 
In advance of preparation of protein extracts, HEK293T cells were cultured in 
Dulbecco’s modified eagle media (DMEM) supplemented with 100 units/mL penicillin, 
100 μg/mL streptomycin, 10 % fetal bovine serum, and 2 mM glutaMAX at 37°C in 5% 
CO2. All tissue culture media and additives were supplied by Gibco.  Cells at ~ 70 % 
confluence on T75 plates were washed and resuspended in PBS, and cell number/mL was 
determined using a haemocytometer to enable the average number of cells per µg total 
protein extract to be calculated later in the analysis. Next, the cells were pelleted at 1,200 
x g, resuspended in 700 μL extraction buffer, and sonicated for 30 s at 20 MHz. The 
lysate was clarified by centrifugation for 1 h at 21,130 x g.  The supernatant was 
collected for immunoblotting and analysis/BCA assay. 
 
Quantitative immunoblotting 
Immunoblotting was performed using mouse anti-PKA subunit primary antibodies 
purchased from BD Biosciences. Antibodies were diluted to 0.8 μg/mL in Tris-buffered 
saline + 0.05 % Tween-20 (TBS-T) supplemented with 10 % milk (w/v) with the 
exception of pan-C antibody (0.5 μg/mL). Experiments were performed using antibodies 
recognizing C subunits (detection range 0.1-100 ng, product number 610981), RI 
subunits (1-100 ng, 610166), RIα (n/a, 610609), RIIα (3-50 ng, 612243), and RIIβ (3-50 
ng, 610626). Primary antibodies were coupled to goat anti-mouse IgG (H+L) poly-
horseradish peroxidase (HRP) secondary antibody (Thermo Fisher Scientific), and 
peroxidase was detected with SuperSignal™ West Dura substrate (Thermo Fisher 
Scientific) using an ImageQuant imaging unit (GE Healthcare Life Sciences). Band 
intensities for reference protein standards and experimental samples were calculated 
using ImageJ (NIH) for background subtraction and pixel integration. For each IB, 
reference curves were established by fitting to Hill functions using iterative least-squares 
refinement with the Levenberg-Marquardt algorithm in ORIGIN software (OriginLab). 
Fitted curves (with typical R2 coefficients > 0.99) were used to determine the protein 
concentration of the given PKA subunit in experimental samples transferred on the same 
nitrocellulose membrane. Calibration experiments were performed to determine optimal 
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sample loading volumes and exposure times that generated signal within the dynamic 
range of the relevant antibody before the full analysis (n=4 for each subunit in each 
extract) was completed. 
 PKA subunit copy numbers per HEK293T cell (Fig. 2C & Table S1) were 
calculated according to the following formula: 
 
€ 
Subunit number (cell-1) =  Subunit/total protein (g/g)Subunit MW (gmol-1)
" 
# 
$ 
% 
& 
' ∗Avogradro's constant (mol-1)∗Total protein extracted per cell (gcell-1)
 
 
Crosslinking coupled to mass spectrometry (XL-MS) 
RIIα-Cβ, RIIβ-Cβ, and RIIβ-Cβ-AKAP18α complexes were crosslinked in 100 μL 
HEPES-NaCl buffer comprising 50 μg RIIα + 50 μg Cβ, 50 μg RIIβ + 50 μg Cβ, and 50 
μg RIIβ + 50 μg Cβ + 5 μg AKAP18α, respectively. The samples were pre-incubated at 
30°C for 10 min shaking at 500 rpm in a Thermomixer (Eppendorf). Crosslinking was 
initiated by addition of 0.5 mM H12/D12 DSS (Creative Molecules) from a 25 mM stock 
prepared in DMSO.  After a further 30 min shaking at 30 °C, crosslinking was quenched 
by addition of 50 mM ammonium bicarbonate from a 1 M stock. During analysis of 
electrophoretically-separated crosslinked samples, AKAP18α was detected by far-
western blotting with V5-tagged RIIα subunits coupled to anti-V5-HRP antibody 
(Thermo Fisher Scientific). Prior to analysis on the mass spectrometer, crosslinked 
samples were treated with a urea/tris(2-carboxyethyl)phosphine (TCEP) solution to 
reduce disulphide bonds, after which free cysteines were alkylated with  iodoacetimide.  
Protein was next digested with trypsin, and the resulting trypsinized peptide mixture was 
treated with formic acid to inhibit trypsin activity. Digested peptides were separated from 
the solution and retained by a solid phase extraction system, and then separated by SEC 
prior to liquid chromatography (LC)-MS/MS analysis on Thermo Scientific Orbitrap 
Elite (RIIβ-containing samples) or Orbitrap Fusion Tribrid (RIIα-containing samples) 
mass spectrometers. Data were searched using xQuest in ion-tag mode with a precursor 
mass tolerance of 10 ppm. For matching of fragment ions, tolerances of 0.2 Da for 
common-ions and 0.3 Da for cross-link ions were applied. Crosslinked samples were 
	   7	  
prepared in duplicate for all complexes, and each of these was measured with technical 
duplicates. Crosslinks were only considered during structural analysis if they registered 
ID scores >20 and deltaS < 0.95. 
 
Quantitative crosslinking coupled to mass spectrometry (qXL-MS)  
For qXL-MS analysis, we compared the intensities of peaks eluting for crosslinks 
between the RIIβ-Cβ and RIIβ-Cβ-AKAP18α samples (n=2, each sample analysed in 
duplicate). Amounts of potential crosslinks were normalized prior to MS by measuring 
peptide bond absorption at 215 nm for each fraction. Only high-confidence crosslinks 
that were identified in all biological experiments were selected for further quantitative 
analysis. Quantities of identified high-quality crosslinks were determined by xTract (37). 
 
Statistical analysis 
Results are presented throughout as mean ± sem. Data were analyzed by two-sided 
Student’s t-test. P values are *P<0.05, **P<0.01, ***P<0.001. 
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SUPPLEMENTARY FIGURE & TABLE LEGENDS 
 
Figure S1. Supporting experiments for UV-induced crosslinking of PKA subunits in 
HEK293T cells (A) We tested if GST-RIAD is capable of pulling down both RIα and 
RIβ. Magnetic glutathione sepharose beads were charged with GST-RIAD and incubated 
with extraction buffer containing 0.11 ng/μL RIα or RIβ. The beads were washed, 
protein was eluted with SDS loading buffer, and RI precipitation was compared by anti-
RI IB. (B) Relative to the input material, according to densitometry, RIα was enriched by 
14.3±1.8-fold (n=3), and RIβ by 15.1±0.6-fold (n=4). This experiment indicates that 
GST-RIAD pulls down both RI isoforms with similar efficiency. (C & D) Effect of 
isoproterenol treatment and timing of UV exposure on RI-C crosslinking in HEK293T 
cells. (C) Control experiment to test whether addition of cAMP prevents RII-C 
crosslinking when crosslinking is performed by UV illumination ‘post-lysis’ following 
isoproterenol stimulation. 10 µM cAMP was added 10 min before UV illumination for 
the + cAMP condition (lane 3). RII-C crosslinking was assessed by anti-RII IB following 
pull-down with GST-AKAP79c93. (D) Whereas the crosslinked RII-C band was 2.15±0.08 
times as intense as the input C subunit band according to anti-C IB, addition of cAMP 
reduced RII-C signal to only 0.04±0.01 as much as the input C subunit. This indicates 
that addition of cAMP during post-lysis UV-induced crosslinking reduces RII-C 
crosslinking by ~ 50-fold (p=0.0014, n=3). (E) Cells were incubated first with SDA, then 
in PBS either with or without 1 μM isoproterenol. After 5 min, the cells were either 
exposed to UV light immediately (‘pre-lysis’, lanes 3 & 4), or UV illumination was 
delayed until after cell lysis (‘post lysis’, lanes 4 & 5). RI subunits were selectively 
precipitated using GST-RIAD attached to glutathione magnetic beads in all cases. RI-C 
subunit association at the moment of UV illumination was revealed by the intensity of the 
band at ~ 90 kD in the anti-C subunit IB as indicated by the arrow. (F) Densitometry 
confirmed that isoproterenol led to reduced RI-C crosslinking both in live cells (‘pre-
lysis’, -84±3%, n=4, p = 1.18 x 10-4), and when UV exposure was delayed until after cell 
lysis (‘post-lysis’, - 63±5%, n=4, p = 9.03 x 10-4). C subunits can bind RII but not RI 
subunits in the absence of Mg2+ and ATP (38). In addition, RI holoenzymes are more 
sensitive to cAMP than RIIβ holoenzymes (1). These differences may explain why C 
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subunits do not re-associate with RI as efficiently as RII (Fig. 2E) upon cell lysis 
following isoproterenol stimulation. 
 
Figure S2. Anti-PKA subunit antibody validation. In advance of quantitative 
immunoblotting experiments with proteins extracts from rat organ and HEK293T cells, 
we assessed the specificity of anti-PKA subunit antibodies sold by BD Biosciences. For 
each antibody, binding was tested to a panel of highly purified human PKA subunits. The 
purity of each subunit used for antibody validation is demonstrated by Coomassie 
staining (A). In panels (B) to (F) the catalog number for BD Biosciences, and the amount 
of PKA subunit loaded in each lane is listed. (B) Pan-C antibody recognized both Cα and 
Cβ with equal efficiency (lanes 1 & 2). This antibody was raised against purified human 
PKA C subunit α isoform residues 18-347.  This region is 94% identical to the equivalent 
region in the β isoform. The antibody is highly sensitive and also proved to be useful for 
light-activated crosslinking experiments. (C) Pan-RI antibody bound equally well to RIα 
and RIβ as expected. This antibody was raised against residues 285-351 of RIα, which 
have 88% identity with the equivalent region of RIβ. On the other hand, antibody 
marketed as being selective for the α isoform of RI (D) also bound to RIβ (lane 4) albeit 
with some preference for RIα (2.3-fold higher signal, D). We therefore did not attempt to 
distinguish relative levels of RIα and RIβ in quantitative IBs. RIIα (E, lane 5) and RIIβ 
(F, lane 6)-specific antibodies showed no cross-reactivity. We therefore proceeded with 
Pan-C, Pan-RI and RII isoform-specific antibodies for determination of PKA subunit 
stoichiometries. 
 
Figure S3. PKA subunit quantitation in rat extracts. Panels A to D show example 
quantitative IBs for determination of PKA subunit concentrations per total protein 
extracted in eight different extract types. In each panel, IBs are shown on the left-hand 
side, and the position of band intensities on reference curves derived from the reference 
protein series are shown on the right (A) Anti-C subunit IB. The reference protein is 
purified Cβ. The following amounts of total extracted protein were loaded (μg):  32.3 
(HEK293T), 13.8 (nerve ending-rich), 11.2 (forebrain), 31.1 (cerebellum), 25.8 (heart), 
101 (liver), 61.4 (lungs), and 47.9 (skeletal muscle). (B) Anti-RI IB. The reference 
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protein is purified RIβ. The following amounts of total extracted protein were loaded 
(μg):  33.3 (HEK293T), 113 (liver), 50.6 (lung), 60.4 (skeletal muscle), 12.3 (nerve 
ending-rich), 17.0 (forebrain), 10.5 (cerebellum), 21.0 (heart). (C) Anti-RIIα IBs. The 
reference protein is purified RIIα.  The following amounts of total extracted protein were 
loaded (μg): 26.0 (HEK293T), 47.3 (nerve ending-rich), 28.5 (forebrain), 31.1 
(cerebellum), 79.9 (heart), 101 (liver), 41.4 (lungs), and 39.7 (skeletal muscle). (D) Anti-
RIIβ IBs. The reference protein is purified RIIβ. The following amounts of total extracted 
protein were loaded (μg): 31.8 (nerve ending-rich), 22.3 (forebrain), 24.9 (cerebellum), 
79.9 (heart), 52.8 (lung), 39.8 (HEK293T), 57.0 (skeletal muscle), 189 (liver). In all cases, 
final average subunit concentrations were determined from the average of four replicates. 
 
Figure S4. Structural insights into type IIα PKA anchoring from XL-MS (A) Each 
sub-panel corresponds to Cβ-RIIα subunits before (lanes 1, 3 & 5) and after (2, 4 & 6) 
DSS crosslinking. The samples were visualized by Coomassie staining (5 μg sample/lane, 
lanes 1 & 2), anti-C IB (25 ng in lane 3; 100 ng in lane 4), and anti-RIIβ IB (12.5 ng/lane, 
lanes 5 & 6). DSS crosslinking interfered with anti-C subunit antibody recognition so it 
was necessary to load more material in lane 4 than 3. (B) Distribution of intralinks (grey) 
and interlinks (black) within Cβ-RIIα. Panel (C) was assembled using PDB ID 2QVS (8), 
and shows the positions of four lysines (Cα atoms as black spheres) in Cβ that were 
detected in interlinks paired to RIIα K71. The surface of RIIα is shown in blue, with Cβ 
in green. Cβ lysines that were not detected in interlinks to RIIα K71 are shown as green 
spheres. The first visible amino acid in the RIIα – Cβ heterodimer crystal structure (8) is 
T91. RIIα K71 (the only lysine within the first 100 amino acids of RIIα) lies midway 
between T91 and the RIIα D/D domain (second helix ends at ~ position 43) so links 
involving this lysine provide information of the path of the linker between the 
autoinhibitory site and D/D domain. Four interlinks were detected between RIIα K71 and 
sites in Cβ, with all four sites falling in the C-lobe of the catalytic domain. RIIα K71 
interlinked strongly to a triad of lysines at the base of the Cβ C-lobe: multiple interlinks 
were detected for lysines 254, 266 & 279 (shown in black). A further interlink was 
detected between RIIα K71 and Cβ K317. This pattern of interlinking is consistent with 
	   11	  
the linker prior to the autoinhibitory site taking a path to the base of the C-lobe. This 
could potentially position the RIIα D/D domain in a similar orientation with respect to 
the C subunit as in the RIIβ holoenzyme (Fig. 4C & D). In comparison to RIIβ-Cβ XL-
MS, there are reasons for caution in interpreting the results of RIIα-Cβ crosslinking. 
Whereas, RIIβ K46 lies at the immediate C-terminus of the D/D domain, the key 
reference K71 in RIIα is mid-way between the D/D domain and autoinhibitory site. 
Furthermore, the pattern of intralinks within RIIα involving RIIα K71 is difficult to 
interpret (Fig. S4B, Table S4) as there is no reference tetrameric reference crystal 
structure for RIIα-Cβ unlike RIIβ-Cβ (51). 
 
Table S1. Calculation of PKA subunit copy numbers per HEK293T cell. Copy 
numbers were determined according to the formula listed under the heading "Quantitative 
immunoblotting" in Supplemental Information. *The MW of Cα was used, since this is 
the predominant isoform in HEK293T cells according to the molecular weight detected 
with pan-C antibody (e.g., Fig 1D). **Average of RIα (42,982 Da) and RIβ (43,073 Da).   
 
Table S2. XL-MS data following RIIβ-Cβ DSS crosslinking. The first column lists the 
amino acid sequence of crosslinked peptides and the positions of the crosslinked lysine 
residues. “deltaS” is a measure for how close the best assigned hit was scored in regard to 
the second best. The peptides are listed in order of “ID-Score”, which is a weighted sum 
of different used to assess the quality of the composite MS2 spectrum as calculated by 
xQuest. 
 
Table S3. XL-MS data following RIIβ-Cβ-AKAP18α DSS crosslinking. Column 
labels are the same as described in the legend to Table S2. 
 
Table S4. XL-MS data following RIIα-Cβ DSS crosslinking. Column labels are the 
same as described in the legend to Table S2. 
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Table S5. Quantitative XL-MS comparison of crosslinking site intensity ± AKAP18α. 
The table lists the relative change in crosslinking between different lysine pairs within 
RIIβ-Cβ upon inclusion of AKAP18α. Lysine pairs are listed starting with the link that 
was most reduced by inclusion of AKAP18α. Changes in abundance are expressed as 
log2 (abundance with AKAP18α/abundance without AKAP18α). p value indicates the 
regression between the two conditions. 
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Table 1. Crosslinks in RIIβ-Cβ affected by addition of AKAP18α. Unique 
crosslinking sites are listed whose abundance either increased by more than 50 %, or 
decreased to less than 50 % upon addition of AKAP18α. p < 0.01 for all sites. Data for 
all 45 unique crosslinking sites that could be reliably quantified are listed in Table S5. 
 
Dynamic Crosslink Ratio (+/-AKAP18α) p value 
Decreased abundance + AKAP18α   
RIIβ K285 - RIIβ K324 0.186 1.32 x 10-9 
Cβ K266 - RIIβ K46 0.345 2.58 x 10-3 
RIIβ K263 - RIIβ K46 0.387 1.58 x 10-5 
RIIβ K285 - RIIβ K46 0.424 1.3 x 10-6 
RIIβ K357 - RIIβ K46 0.462 1.17 x 10-4 
Increased abundance + AKAP18α   
Cβ 16 - Cβ 292 2.12 1.26 x 10-6 
Cβ 21 - Cβ 83 1.92 2.23 x 10-4 
Cβ 76 - Cβ 83 1.64 4.07 x 10-6 
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Table S1. Calculation of PKA subunit copy numbers per HEK293T cell. Copy 
numbers were determined according to the formula listed under the heading "Quantitative 
immunoblotting" in Supplemental Information. *The MW of Cα was used, since this is 
the predominant isoform in HEK293T cells according to the molecular weight detected 
with pan-C antibody (e.g., Fig 1D). **Average of RIα (42,982 Da) and RIβ (43,073 Da).   
 
PKA Subunit  
Fraction of HEK293T 
cell extract (ppm) 
Subunit 
MW (Da) 
Copies per g 
extract (x1018) 
Copies per cell 
(x106) 
C 56.6±4 40590* 0.840±0.06 0.242±0.021 
RI 183±34 43028** 2.56±0.48 0.734±0.13
RIIα 409±72 45518 5.41±0.95 1.54±0.23 
RIIβ 82.9±21 46302 1.08±0.27 0.300±0.069
 
	   1	  
Table S2. XL-MS data following RIIβ-Cβ DSS crosslinking. The first column lists the 
amino acid sequence of crosslinked peptides and the positions of the crosslinked lysine 
residues. “deltaS” is a measure for how close the best assigned hit was scored in regard to 
the second best. The peptides are listed in order of “ID-Score”, which is a weighted sum 
of different used to assess the quality of the composite MS2 spectrum as calculated by 
xQuest. 
 
Crosslinked Peptide Sequence Protein 1 Protein 2 Position 1 Position 2 deltaS 
ID-
score 
FPSHFSSDLKDLLR-KGTAR-a10-b1 Cβ RIIβ 266	   46	   0.36 49.45 
RKGKSEVEENGAVEIAR-
GQYFGELALVTNKPR-a2-b13 RIIβ RIIβ 326	   357	   0 46.95 
IIHPKTDDQR-LKVVDVIGTK-a5-b2 RIIβ RIIβ 135	   285	   0.67 46.2 
RKGKSEVEENGAVEIAR-
GQYFGELALVTNKPR-a4-b13 RIIβ RIIβ 328	   357	   0 45.47 
LKQIEHTLNEK-ILDKQK-a2-b4 Cβ Cβ 83	   76	   0.74 45.25 
KGKSEVEENGAVEIAR-
GQYFGELALVTNKPR-a3-b13 RIIβ RIIβ 328	   357	   0 45.13 
GKSEVEENGAVEIAR-
GQYFGELALVTNKPR-a2-b13 RIIβ RIIβ 328	   357	   0 45.12 
ATEQYYAMKILDK-VMLVKHK-a9-b5 Cβ Cβ 72	   61	   0.57 44.43 
KMYESFIESLPFLK-IIVKNNAK-a1-b4 RIIβ RIIβ 263	   256	   0 44 
KGKSEVEENGAVEIAR-ITMKR-a1-b4 RIIβ RIIβ 326	   324	   0.93 43.45 
KGKSEVEENGAVEIAR-ITMKR-a3-b4 RIIβ RIIβ 328	   324	   0.93 43.41 
NLLQVDLTKR-IVSGKVR-a9-b5 Cβ Cβ 279	   254	   0.47 43.36 
IIHPKTDDQR-IIHPKTDDQR-a5-b5 RIIβ RIIβ 135	   135	   0 43.03 
NGVSDIKTHK-AKEDFLR-a7-b2 Cβ Cβ 292	   23	   0.72 42.73 
KMYESFIESLPFLK-KGTAR-a1-b1 RIIβ RIIβ 263	   46	   0 42.2 
LKVVDVIGTK-ITMKR-a2-b4 RIIβ RIIβ 285	   324	   0 41.89 
KMYESFIESLPFLK-NNAKKR-a1-b4 RIIβ RIIβ 263	   260	   0 41.6 
ATEQYYAMKILDK-VVKLK-a9-b3 Cβ Cβ 72	   81	   0.48 40.88 
KGKSEVEENGAVEIAR-KGTAR-a3-b1 RIIβ RIIβ 328	   44	   0.45 40.87 
RKMYESFIESLPFLK-IIVKNNAK-a2-b4 RIIβ RIIβ 263	   256	   0.79 40.73 
FPSHFSSDLKDLLR-AKEDFLR-a10-b2 Cβ Cβ 266	   23	   0.58 40.68 
IIHPKTDDQR-KGTAR-a5-b1 RIIβ RIIβ 135	   46	   0 40.51 
LVKDGEHVIDQGDDGDNFYVIDR-KGTAR-
a3-b1 RIIβ RIIβ 174	   46	   0 40.26 
LKQIEHTLNEKR-ILDKQK-a11-b4 Cβ Cβ 92	   76	   0 40.01 
KGKSEVEENGAVEIAR-
GQYFGELALVTNKPR-a1-b13 RIIβ RIIβ 326	   357	   0 39.45 
GKSEVEENGAVEIAR-ITMKRK-a2-b4 RIIβ RIIβ 328	   324	   0.94 39.18 
RKMYESFIESLPFLK-NNAKK-a2-b4 RIIβ RIIβ 263	   260	   0.95 38.93 
KGKSEVEENGAVEIAR-KGTAR-a1-b1 RIIβ RIIβ 326	   46	   0.38 38.92 
LKQIEHTLNEKR-AKEDFLR-a2-b2 Cβ Cβ 83	   23	   0 38.7 
LKVVDVIGTK-KGTAR-a2-b1 RIIβ RIIβ 285	   46	   0 38.35 
KGSEVESVKEFLAK-NGVSDIKTHK-a9-b7 Cβ Cβ 16	   292	   0.93 38.18 
KKTLGTGSFGR-VMLVKHK-a2-b5 Cβ Cβ 47	   61	   0 38.12 
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LKVVDVIGTK-IIVKNNAK-a2-b4 RIIβ RIIβ 285	   256	   0 37.95 
IIHPKTDDQR-IIVKNNAK-a5-b4 RIIβ RIIβ 135	   256	   0 37.55 
KKTLGTGSFGR-VEAPFIPKFR-a2-b8 Cβ Cβ 47	   317	   0.9 37.47 
HKATEQYYAMKILDKQK-VVKLK-a11-b3 Cβ Cβ 72	   81	   0.74 37.44 
FGNLKNGVSDIKTHK-AKEDFLRK-a12-b2 Cβ Cβ 292	   23	   0 37.21 
FGNLKNGVSDIKTHK-AKEDFLR-a12-b2 Cβ Cβ 292	   23	   0.27 37.12 
KKTLGTGSFGR-KVEAPFIPKFR-a2-b9 Cβ Cβ 47	   317	   0.77 36.83 
KMYESFIESLPFLK-NNAKK-a1-b4 RIIβ RIIβ 263	   260	   0 36.51 
LKVVDVIGTK-RVKGR-a2-b3 RIIβ Cβ 285	   192	   0 36.35 
NGVSDIKTHK-AKEDFLRK-a7-b2 Cβ Cβ 292	   23	   0.76 36.21 
HKATEQYYAMKILDK-LKQIEHTLNEKR-
a11-b2 Cβ Cβ 72	   83	   0.26 36.19 
GKSEVEENGAVEIAR-ITMKR-a2-b4 RIIβ RIIβ 328	   324	   0.27 36.19 
ILDKQK-VVKLK-a4-b3 Cβ Cβ 76	   81	   0.89 36.05 
LKQIEHTLNEKR-QKVVK-a2-b2 Cβ Cβ 83	   78	   0 36.05 
LKQIEHTLNEKR-ILDKQK-a2-b4 Cβ Cβ 83	   76	   0.73 36.04 
LKQIEHTLNEK-ILDKQKVVK-a2-b6 Cβ Cβ 83	   78	   0.87 35.74 
LKVVDVIGTK-NNAKK-a2-b4 RIIβ RIIβ 285	   260	   0.79 35.65 
KKTLGTGSFGR-KVEAPFIPKFR-a1-b9 Cβ Cβ 46	   317	   0.71 35.1 
LVKDGEHVIDQGDDGDNFYVIDR-
IIVKNNAK-a3-b4 RIIβ RIIβ 174	   256	   0.18 35 
HKATEQYYAMKILDK-LKQIEHTLNEK-a11-
b2 Cβ Cβ 72	   83	   0.75 34.9 
LVKDGEHVIDQGDDGDNFYVIDR-
IVSGKVR-a3-b5 RIIβ Cβ 174	   254	   0.32 34.82 
GQYFGELALVTNKPR-ITMKR-a13-b4 RIIβ RIIβ 357	   324	   0 34.79 
NGVSDIKTHKWFATTDWIAIYQR-
AKEDFLR-a10-b2 Cβ Cβ 295	   23	   0.26 34.64 
RKMYESFIESLPFLK-ILDKQK-a2-b4 RIIβ Cβ 263	   76	   0.69 34.62 
GQYFGELALVTNKPR-KGTAR-a13-b1 RIIβ RIIβ 357	   46	   0 34.42 
QIEHTLNEKR-ILDKQK-a9-b4 Cβ Cβ 92	   76	   0 34.25 
LKQIEHTLNEKR-ILDKQKVVK-a2-b6 Cβ Cβ 83	   78	   0 34.16 
KMYESFIESLPFLK-RVKGR-a1-b3 RIIβ Cβ 263	   192	   0.37 33.91 
LVKDGEHVIDQGDDGDNFYVIDR-
RIIVKNNAK-a3-b5 RIIβ RIIβ 174	   256	   0 33.79 
NGVSDIKTHK-KVEAPFIPK-a7-b1 Cβ Cβ 292	   309	   0.81 33.79 
KGSEVESVKEFLAK-AKEDFLR-a9-b2 Cβ Cβ 16	   23	   0.77 33.42 
LKQIEHTLNEK-QKVVK-a2-b2 Cβ Cβ 83	   78	   0.77 33.38 
QIEHTLNEKR-AKEDFLR-a9-b2 Cβ Cβ 92	   23	   0 33.34 
LKVVDVIGTK-VVKLK-a2-b3 RIIβ Cβ 285	   81	   0.38 33.24 
RKGKSEVEENGAVEIAR-ITMKR-a4-b4 RIIβ RIIβ 328	   324	   0.33 33.1 
RKGKSEVEENGAVEIAR-ITMKR-a2-b4 RIIβ RIIβ 326	   324	   0.31 32.73 
HKATEQYYAMKILDK-VVKLK-a11-b3 Cβ Cβ 72	   81	   0.57 32.69 
HKATEQYYAMK-KKTLGTGSFGR-a2-b2 Cβ Cβ 63	   47	   0.52 32.69 
HKATEQYYAMKILDKQK-AKEDFLR-a11-
b2 Cβ Cβ 72	   23	   0.74 32.64 
LVKDGEHVIDQGDDGDNFYVIDR-
IIHPKTDDQR-a3-b5 RIIβ RIIβ 174	   135	   0.69 32.57 
KWENPPPSNAGLEDFER-KVEAPFIPK-a1-
b1 Cβ Cβ 29	   309	   0 31.72 
ATEQYYAMKILDK-LKQIEHTLNEKR-a9-b2 Cβ Cβ 72	   83	   0.37 31.56 
MYESFIESLPFLKSLEFSER-KGTAR-a13-
b1 RIIβ RIIβ 276	   46	   0 31.48 
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KGKSEVEENGAVEIAR-NNAKK-a3-b4 RIIβ RIIβ 328	   260	   0.56 31.08 
ATEQYYAMKILDK-LKQIEHTLNEKR-a9-
b11 Cβ Cβ 72	   92	   0.21 31.06 
FPSHFSSDLKDLLR-IVSGKVR-a10-b5 Cβ Cβ 266	   254	   0.73 30.91 
KMYESFIESLPFLK-NNAKKR-a1-b5 RIIβ RIIβ 263	   261	   0.92 30.9 
KWENPPPSNAGLEDFER-NGVSDIKTHK-
a1-b7 Cβ Cβ 29	   292	   0 30.77 
AKEDFLR-RVKGR-a2-b3 Cβ Cβ 23	   192	   0 30.56 
KVEAPFIPK-AKEDFLR-a1-b2 Cβ Cβ 309	   23	   0 30.51 
ATEQYYAMKILDK-LKQIEHTLNEK-a9-b2 Cβ Cβ 72	   83	   0.36 29.82 
ATEQYYAMKILDK-QIEHTLNEKR-a9-b9 Cβ Cβ 72	   92	   0 29.68 
AKEDFLRK-RVKGR-a2-b3 Cβ Cβ 23	   192	   0.51 29.63 
ATEQYYAMKILDK-RVKGR-a9-b3 Cβ Cβ 72	   192	   0.6 29.39 
KWENPPPSNAGLEDFER-AKEDFLR-a1-
b2 Cβ Cβ 29	   23	   0.9 29.07 
FGNLKNGVSDIKTHK-
KGSEVESVKEFLAK-a12-b9 Cβ Cβ 292	   16	   0.82 28.68 
KMYESFIESLPFLK-LKVVDVIGTK-a1-b2 RIIβ RIIβ 263	   285	   0 28.64 
DLKPENLLIDHQGYIQVTDFGFAKR-
AKEDFLR-a24-b2 Cβ Cβ 189	   23	   0.37 28.33 
GQYFGELALVTNKPRAASAHAIGTVK-
LKQIEHTLNEKR-a13-b11 RIIβ Cβ 357	   92	   0.21 28.11 
KMYESFIESLPFLKSLEFSER-KGTAR-a14-
b1 RIIβ RIIβ 276	   46	   0.3 27.76 
LKQIEHTLNEKR-RVKGR-a2-b3 Cβ Cβ 83	   192	   0 27.69 
KWENPPPSNAGLEDFER-IVSGKVR-a1-b5 Cβ Cβ 29	   254	   0 27.65 
QIEHTLNEKR-VVKLK-a9-b3 Cβ Cβ 92	   81	   0.32 27.61 
LKQIEHTLNEKR-ILDKQKVVK-a2-b4 Cβ Cβ 83	   76	   0.88 27.54 
RFGNLKNGVSDIKTHK-AKEDFLR-a13-b2 Cβ Cβ 292	   23	   0.58 27.51 
LEYSFKDNSNLYMVMEYVPGGEMFSHLR-
ILDKQK-a6-b4 Cβ Cβ 111	   76	   0 27.34 
KWENPPPSNAGLEDFER-
ATEQYYAMKILDKQK-a1-b13 Cβ Cβ 29	   76	   0.35 26.82 
KWENPPPSNAGLEDFER-
LKQIEHTLNEKR-a1-b11 Cβ Cβ 29	   92	   0 26.52 
HKATEQYYAMKILDK-LKQIEHTLNEKR-
a11-b11 Cβ Cβ 72	   92	   0.36 26.39 
KMYESFIESLPFLK-RIIVKNNAK-a1-b5 RIIβ RIIβ 263	   256	   0.87 25.21 
ATEQYYAMKILDKQK-LKQIEHTLNEKR-
a9-b2 Cβ Cβ 72	   83	   0.69 25.18 
KWENPPPSNAGLEDFER-
LKQIEHTLNEKR-a1-b2 Cβ Cβ 29	   83	   0 25.17 
FGNLKNGVSDIKTHK-NLLQVDLTKR-a5-
b9 Cβ Cβ 285	   279	   0.38 25.16 
FPSHFSSDLKDLLRNLLQVDLTKR-
IVSGKVR-a10-b5 Cβ Cβ 266	   254	   0.56 25.13 
GQYFGELALVTNKPR-FGNLKNGVSDIK-
a13-b5 RIIβ Cβ 357	   285	   0.33 24.94 
NLLQVDLTKRFGNLK-NGVSDIKTHK-a9-
b7 Cβ Cβ 279	   292	   0.91 24.68 
GQYFGELALVTNKPRAASAHAIGTVK-
LKQIEHTLNEKR-a13-b2 RIIβ Cβ 357	   83	   0.17 24.65 
LKQIEHTLNEK-RVKGR-a2-b3 Cβ Cβ 83	   192	   0.49 24.35 
ATEQYYAMKILDK-QKVVKLK-a9-b5 Cβ Cβ 72	   81	   0.9 23.59 
KWENPPPSNAGLEDFER-QIEHTLNEKR-
a1-b9 Cβ Cβ 29	   92	   0.35 23.45 
ATEQYYAMKILDKQK-NGVSDIKTHK-a13-
b7 Cβ Cβ 76	   292	   0.93 22.86 
HKATEQYYAMKILDK-QIEHTLNEKR-a11-
b9 Cβ Cβ 72	   92	   0.4 22.67 
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LKQIEHTLNEK-LKVVDVIGTK-a2-b2 Cβ RIIβ 83	   285	   0.5 22.52 
RKMYESFIESLPFLKSLEFSER-KGTAR-
a15-b1 RIIβ RIIβ 276	   46	   0 22.27 
HKATEQYYAMKILDKQK-QIEHTLNEKR-
a11-b9 Cβ Cβ 72	   92	   0.76 22.07 
HKATEQYYAMKILDKQK-LKQIEHTLNEKR-
a11-b2 Cβ Cβ 72	   83	   0.71 21.62 
RKMYESFIESLPFLKSLEFSER-IIVKNNAK-
a15-b4 RIIβ RIIβ 276	   256	   0.82 21.54 
NLDPEQMSQVLDAMFEKLVK-
IIHPKTDDQR-a17-b5 RIIβ RIIβ 171	   135	   0.53 21.33 
LKQIEHTLNEKR-AKEDFLR-a11-b2 Cβ Cβ 92	   23	   0 21.26 
ATEQYYAMKILDKQK-VVKLK-a9-b3 Cβ Cβ 72	   81	   0.81 20.99 
LKQIEHTLNEKR-HKATEQYYAMK-a2-b2 Cβ Cβ 83	   63	   0 20.88 
NGVSDIKTHK-QIEHTLNEKR-a7-b9 Cβ Cβ 292	   92	   0 20.68 
QIEHTLNEKR-ILDKQKVVK-a9-b4 Cβ Cβ 92	   76	   0.91 20.34 
KWENPPPSNAGLEDFER-
KKTLGTGSFGR-a1-b2 Cβ Cβ 29	   47	   0.36 20.14 
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Table S3. XL-MS data following RIIβ-Cβ-AKAP18α DSS crosslinking. The first 
column lists the amino acid sequence of crosslinked peptides and the positions of the 
crosslinked lysine residues. “deltaS” is a measure for how close the best assigned hit was 
scored in regard to the second best. The peptides are listed in order of “ID-Score”, which 
is a weighted sum of different used to assess the quality of the composite MS2 spectrum 
as calculated by xQuest. 
 
Crosslinked Peptide Sequence Protein 1 Protein 2 Position 1 Position 2 deltaS ID-score 
LKQIEHTLNEK-ILDKQK-a2-b4 Cβ Cβ 83	   76	   0.52 50.16 
GKSEVEENGAVEIAR-GQYFGELALVTNKPR-
a2-b13 RIIβ RIIβ 328	   357	   0 45.44 
RKGKSEVEENGAVEIAR-
GQYFGELALVTNKPR-a2-b13 RIIβ RIIβ 326	   357	   0 44.79 
KMYESFIESLPFLK-NNAKKR-a1-b4 RIIβ RIIβ 263	   260	   0.4 44.5 
IIHPKTDDQR-LKVVDVIGTK-a5-b2 RIIβ RIIβ 135	   285	   0 44.42 
FPSHFSSDLKDLLR-KGTAR-a10-b1 Cβ RIIβ 266	   46	   0.48 44.41 
NLLQVDLTKR-IVSGKVR-a9-b5 Cβ Cβ 279	   254	   0.63 42.61 
KMYESFIESLPFLK-IIVKNNAK-a1-b4 RIIβ RIIβ 263	   256	   0 42.35 
HKATEQYYAMKILDKQK-VVKLK-a11-b3 Cβ Cβ 72	   81	   0.76 42.24 
NGVSDIKTHK-AKEDFLR-a7-b2 Cβ Cβ 292	   23	   0 41.27 
KGKSEVEENGAVEIAR-ITMKR-a1-b4 RIIβ RIIβ 326	   324	   0.94 41.25 
ILDKQK-VVKLK-a4-b3 Cβ Cβ 76	   81	   0.88 41.17 
KGKSEVEENGAVEIAR-ITMKR-a3-b4 RIIβ RIIβ 328	   324	   0.94 41.05 
KGSEVESVKEFLAK-NGVSDIKTHK-a9-b7 Cβ Cβ 16	   292	   0.57 40.47 
KKTLGTGSFGR-VEAPFIPKFR-a2-b8 Cβ Cβ 47	   317	   0.92 40.23 
LKQIEHTLNEKR-ILDKQK-a11-b4 Cβ Cβ 92	   76	   0 40.07 
LKQIEHTLNEK-AKEDFLR-a2-b2 Cβ Cβ 83	   23	   0.6 38.43 
KKTLGTGSFGR-VMLVKHK-a2-b5 Cβ Cβ 47	   61	   0 38.36 
AKEDFLRK-RVKGR-a2-b3 Cβ Cβ 23	   192	   0.52 37.98 
LKVVDVIGTK-KGTAR-a2-b1 RIIβ RIIβ 285	   46	   0 37.96 
LVKDGEHVIDQGDDGDNFYVIDR-KGTAR-a3-
b1 RIIβ RIIβ 174	   46	   0 37.89 
ATEQYYAMKILDK-VMLVKHK-a9-b5 Cβ Cβ 72	   61	   0.56 37.59 
LKQIEHTLNEKR-AKEDFLR-a11-b2 Cβ Cβ 92	   23	   0 37.04 
LVKDGEHVIDQGDDGDNFYVIDR-IIVKNNAK-
a3-b4 RIIβ RIIβ 174	   256	   0.22 36.73 
KMYESFIESLPFLK-KGTAR-a1-b1 RIIβ RIIβ 263	   46	   0 36.55 
LKQIEHTLNEKR-ILDKQKVVK-a2-b6 Cβ Cβ 83	   78	   0.88 36.5 
KVEAPFIPKFR-AKEDFLR-a9-b2 Cβ Cβ 317	   23	   0.36 36.29 
IIHPKTDDQR-KGTAR-a5-b1 RIIβ RIIβ 135	   46	   0.46 35.89 
LKVVDVIGTK-NNAKK-a2-b4 RIIβ RIIβ 285	   260	   0 35.82 
HKATEQYYAMKILDK-LKQIEHTLNEKR-a11-
b2 Cβ Cβ 72	   83	   0.43 35.37 
LVKDGEHVIDQGDDGDNFYVIDR-IVSGKVR-
a3-b5 RIIβ Cβ 174	   254	   0.17 34.9 
LKVVDVIGTK-IIVKNNAK-a2-b4 RIIβ RIIβ 285	   256	   0 34.62 
HKATEQYYAMKILDK-LKQIEHTLNEKR-a11- Cβ Cβ 72	   92	   0.32 34.59 
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HKATEQYYAMKILDKQK-AKEDFLR-a11-b2 Cβ Cβ 72	   23	   0.68 34.29 
HKATEQYYAMK-AKEDFLR-a2-b2 Cβ Cβ 63	   23	   0 33.97 
KGSEVESVKEFLAK-AKEDFLR-a9-b2 Cβ Cβ 16	   23	   0.7 33.9 
LVKDGEHVIDQGDDGDNFYVIDR-
IIHPKTDDQR-a3-b5 RIIβ RIIβ 174	   135	   0 33.36 
AKEDFLR-VMLVKHK-a2-b5 Cβ Cβ 23	   61	   0 33.36 
IIHPKTDDQR-IIVKNNAK-a5-b4 RIIβ RIIβ 135	   256	   0 33.19 
HKATEQYYAMK-ILDKQK-a2-b4 Cβ Cβ 63	   76	   0 32.97 
VMLVKHK-ILDKQK-a5-b4 Cβ Cβ 61	   76	   0 32.54 
GQYFGELALVTNKPR-KGTAR-a13-b1 RIIβ RIIβ 357	   46	   0 32.41 
KKTLGTGSFGR-KVEAPFIPKFR-a1-b9 Cβ Cβ 46	   317	   0.79 32.41 
NGVSDIKTHK-KVEAPFIPK-a7-b1 Cβ Cβ 292	   309	   0 32.36 
KWENPPPSNAGLEDFER-NGVSDIKTHK-a1-
b7 Cβ Cβ 29	   292	   0.31 32.19 
KWENPPPSNAGLEDFER-ILDKQK-a1-b4 Cβ Cβ 29	   76	   0 32.07 
DLKPENLLIDHQGYIQVTDFGFAKR-
AKEDFLR-a24-b2 Cβ Cβ 189	   23	   0.29 32.03 
FGNLKNGVSDIK-AKEDFLR-a5-b2 Cβ Cβ 285	   23	   0 31.84 
LKQIEHTLNEKR-ILDKQKVVK-a11-b6 Cβ Cβ 92	   78	   0.75 31.51 
LKVVDVIGTK-VVKLK-a2-b3 RIIβ Cβ 285	   81	   0 31.35 
KWENPPPSNAGLEDFER-KVEAPFIPK-a1-b1 Cβ Cβ 29	   309	   0.42 30.72 
LKQIEHTLNEKR-HKATEQYYAMK-a2-b2 Cβ Cβ 83	   63	   0.4 30.52 
QIEHTLNEKR-VVKLK-a9-b3 Cβ Cβ 92	   81	   0 29.73 
KVEAPFIPK-AKEDFLR-a1-b2 Cβ Cβ 309	   23	   0 29.51 
LKQIEHTLNEKR-HKATEQYYAMK-a11-b2 Cβ Cβ 92	   63	   0 29.29 
LKVVDVIGTK-ITMKR-a2-b4 RIIβ RIIβ 285	   324	   0 28.93 
NLLQVDLTKRFGNLK-NGVSDIKTHK-a9-b7 Cβ Cβ 279	   292	   0.91 27.85 
KMYESFIESLPFLKSLEFSER-KGTAR-a14-b1 RIIβ RIIβ 276	   46	   0.36 27.07 
NGVSDIKTHK-EFLAKAK-a7-b5 Cβ Cβ 292	   21	   0.72 26.75 
KWENPPPSNAGLEDFER-LKQIEHTLNEKR-
a1-b11 Cβ Cβ 29	   92	   0.28 26.43 
NGVSDIKTHK-QIEHTLNEKR-a7-b9 Cβ Cβ 292	   92	   0.7 26.17 
HKATEQYYAMKILDKQK-
KWENPPPSNAGLEDFER-a11-b1 Cβ Cβ 72	   29	   0.51 25.99 
KMYESFIESLPFLK-LKVVDVIGTK-a1-b2 RIIβ RIIβ 263	   285	   0.48 25.77 
FGNLKNGVSDIK-ICEKDR-a5-b4 Cβ AKAP18α 285	   19	   0.86 24.44 
ATEQYYAMKILDKQK-NGVSDIKTHK-a13-b7 Cβ Cβ 76	   292	   0.94 24.39 
QIEHTLNEKR-VMLVKHK-a9-b5 Cβ Cβ 92	   61	   0 24 
KWENPPPSNAGLEDFER-LKQIEHTLNEKR-
a1-b2 Cβ Cβ 29	   83	   0 23.73 
FGNLKNGVSDIKTHK-KGSEVESVKEFLAK-
a5-b9 Cβ Cβ 285	   16	   0.54 23.66 
KGSEVESVKEFLAKAK-ILDKQK-a9-b4 Cβ Cβ 16	   76	   0.89 22.35 
KWENPPPSNAGLEDFER-HKATEQYYAMK-
a1-b2 Cβ Cβ 29	   63	   0.24 22.01 
ATEQYYAMKILDKQK-NGVSDIKTHK-a9-b7 Cβ Cβ 72	   292	   0.38 21.23 
AVQQYLEETQNKKQPGEGNSTKAEEGDR-
KMYESFIESLPFLK-a22-b1 AKAP18α RIIβ 65	   263	   0 21.07 
ATEQYYAMKILDK-EFLAKAK-a9-b5 Cβ Cβ 72	   21	   0 20.79 
FGNLKNGVSDIKTHK-NLLQVDLTKR-a5-b9 Cβ Cβ 285	   279	   0.65 20.68 
KTLGTGSFGRVMLVK-ILDKQK-a1-b4 Cβ Cβ 47	   76	   0.77 20.65 
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Table S4. XL-MS data following RIIα-Cβ DSS crosslinking. The first column lists the 
amino acid sequence of crosslinked peptides and the positions of the crosslinked lysine 
residues. “deltaS” is a measure for how close the best assigned hit was scored in regard to 
the second best. The peptides are listed in order of “ID-Score”, which is a weighted sum 
of different used to assess the quality of the composite MS2 spectrum as calculated by 
xQuest. 
 
Crosslinked Peptide Sequence Protein 1 Protein 2 Position 1 Position 2 deltaS 
ID-
score 
TKSNKDGGNQEVEIAR-SNKDGGNQEVEIAR-a2-b3 RIIα RIIα 311 314 0.75 54.11 
KMFESFIESVPLLK-MKIVDVIGEK-a1-b2 RIIα RIIα 246 268 0 49.14 
NISHYEEQLVKMFGSSVDLGNLGQ-
TKSNKDGGNQEVEIAR-a11-b5 RIIα RIIα 387 314 0 48.79 
NISHYEEQLVKMFGSSVDLGNLGQ-
TKSNKDGGNQEVEIAR-a11-b2 RIIα RIIα 387 311 0 47.93 
KVEAPFIPK-AKEDFLR-a1-b2 Cβ Cβ 309 23 0 47.4 
SNKDGGNQEVEIAR-SNKDGGNQEVEIAR-a3-b3 RIIα RIIα 314 314 0 45.9 
NLLQVDLTKR-IVSGKVR-a9-b5 Cβ Cβ 279 254 0.42 45.65 
TKSNKDGGNQEVEIAR-SNKDGGNQEVEIAR-a5-b3 RIIα RIIα 314 314 0.88 44.6 
NISHYEEQLVKMFGSSVDLGNLGQ-
SNKDGGNQEVEIAR-a11-b3 RIIα RIIα 387 314 0 43.7 
MKIVDVIGEK-ILDKQK-a2-b4 RIIα Cβ 268 76 0 43.25 
MKIVDVIGEK-IYKDGER-a2-b3 RIIα RIIα 268 279 0 42.83 
TKSNKDGGNQEVEIAR-TKSNKDGGNQEVEIAR-a2-b2 RIIα RIIα 311 311 0.79 42.79 
TKSNKDGGNQEVEIAR-VIHPKTDEQR-a5-b5 RIIα RIIα 314 118 0.4 41.46 
TKSNKDGGNQEVEIAR-TKSNKDGGNQEVEIAR-a5-b5 RIIα RIIα 314 314 0.8 41.38 
SNKDGGNQEVEIAR-IYKDGER-a3-b3 RIIα RIIα 314 279 0 41.36 
LKQIEHTLNEKR-ILDKQK-a11-b4 Cβ Cβ 92 76 0 41.14 
KMFESFIESVPLLK-IIVKNNAK-a1-b4 RIIα RIIα 246 239 0 41.05 
FGNLKNGVSDIKTHK-AKEDFLR-a12-b2 Cβ Cβ 292 23 0 40.92 
VIHPKTDEQR-RIIVKNNAK-a5-b5 RIIα RIIα 118 239 0 40.91 
HKATEQYYAMK-KKTLGTGSFGR-a2-b2 Cβ Cβ 63 47 0 40.69 
LKQIEHTLNEK-ILDKQKVVK-a2-b6 Cβ Cβ 83 78 0.94 40.49 
LKQIEHTLNEK-ILDKQK-a2-b4 Cβ Cβ 83 76 0 40.14 
LKQIEHTLNEKR-MKIVDVIGEK-a2-b2 Cβ RIIα 83 268 0 40.12 
GTYDILVTKDNQTR-MKIVDVIGEKIYK-a9-b2 RIIα RIIα 186 268 0.59 39.88 
GTYDILVTKDNQTR-MKIVDVIGEK-a9-b2 RIIα RIIα 186 268 0.57 39.83 
RNISHYEEQLVKMFGSSVDLGNLGQ-
TKSNKDGGNQEVEIAR-a12-b5 RIIα RIIα 387 314 0.5 39.16 
RKMFESFIESVPLLK-IIVKNNAK-a2-b4 RIIα RIIα 246 239 0.82 39.06 
VIHPKTDEQR-IIVKNNAK-a5-b4 RIIα RIIα 118 239 0 38.1 
KKTLGTGSFGR-VEAPFIPKFR-a2-b8 Cβ Cβ 47 317 0.79 37.97 
TKSNKDGGNQEVEIAR-VIHPKTDEQR-a2-b5 RIIα RIIα 311 118 0.4 37.5 
KVEAPFIPKFR-VMLVKHK-a9-b5 Cβ Cβ 317 61 0 37.29 
AKEDFLR-VMLVKHK-a2-b5 Cβ Cβ 23 61 0 37.08 
KKTLGTGSFGR-VMLVKHK-a2-b5 Cβ Cβ 47 61 0 36.98 
DLKPENLLIDHQGYIQVTDFGFAKR-AKEDFLR-a24-b2 Cβ Cβ 189 23 0.36 36.83 
LKQIEHTLNEKR-ILDKQKVVK-a2-b6 Cβ Cβ 83 78 0.67 36.64 
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KMFESFIESVPLLK-NNAKKR-a1-b4 RIIα RIIα 246 243 0 36.54 
TKSNKDGGNQEVEIAR-IYKDGER-a2-b3 RIIα RIIα 311 279 0.22 36.37 
LKQIEHTLNEKR-ILDKQK-a2-b4 Cβ Cβ 83 76 0 36.2 
NGVSDIKTHK-AKEDFLR-a7-b2 Cβ Cβ 292 23 0 36.01 
THKWFATTDWIAIYQR-FGNLKNGVSDIK-a3-b5 Cβ Cβ 295 285 0 35.7 
NGVSDIKTHK-AKEDFLRK-a7-b2 Cβ Cβ 292 23 0.64 35.66 
LKQIEHTLNEKR-ILDKQKVVK-a2-b4 Cβ Cβ 83 76 0.73 35.37 
VIHPKTDEQR-IYKDGER-a5-b3 RIIα RIIα 118 279 0 35.32 
GTYDILVTKDNQTR-GTYDILVTKDNQTR-a9-b9 RIIα RIIα 186 186 0.82 35.11 
RKMFESFIESVPLLK-IIVKNNAKK-a2-b8 RIIα RIIα 246 243 0.47 35 
TKSNKDGGNQEVEIAR-GTYDILVTKDNQTR-a5-b9 RIIα RIIα 314 186 0.69 34.86 
IVKADEHVIDQGDDGDNFYVIER-MKIVDVIGEK-a3-b2 RIIα RIIα 157 268 0 34.71 
SNKDGGNQEVEIAR-IIVKNNAK-a3-b4 RIIα RIIα 314 239 0 34.7 
VIHPKTDEQR-ILDKQK-a5-b4 RIIα Cβ 118 76 0 34.68 
TKSNKDGGNQEVEIAR-MKIVDVIGEK-a2-b2 RIIα RIIα 311 268 0.44 34.62 
GTYDILVTKDNQTR-VIHPKTDEQR-a9-b5 RIIα RIIα 186 118 0.5 34.53 
IVKADEHVIDQGDDGDNFYVIER-VIHPKTDEQR-a3-b5 RIIα RIIα 157 118 0.41 34.48 
FPSHFSSDLKDLLR-IVSGKVR-a10-b5 Cβ Cβ 266 254 0 34.44 
GTYDILVTKDNQTR-SNKDGGNQEVEIAR-a9-b3 RIIα RIIα 186 314 0.62 34.29 
SNKDGGNQEVEIAR-NNAKKR-a3-b4 RIIα RIIα 314 243 0 34.29 
KKTLGTGSFGR-KVEAPFIPKFR-a2-b9 Cβ Cβ 47 317 0 34.05 
KKTLGTGSFGR-VMLVKHK-a1-b5 Cβ Cβ 46 61 0 33.96 
NGVSDIKTHKWFATTDWIAIYQR-AKEDFLR-a10-b2 Cβ Cβ 295 23 0 33.93 
GTYDILVTKDNQTR-IVSGKVR-a9-b5 RIIα Cβ 186 254 0.54 33.77 
TKSNKDGGNQEVEIAR-MKIVDVIGEK-a5-b2 RIIα RIIα 314 268 0.44 33.75 
FGNLKNGVSDIK-NLLQVDLTKR-a5-b9 Cβ Cβ 285 279 0 33.45 
TKSNKDGGNQEVEIAR-IYKDGER-a5-b3 RIIα RIIα 314 279 0.34 33.43 
NGVSDIKTHKWFATTDWIAIYQR-AKEDFLR-a7-b2 Cβ Cβ 292 23 0 33.38 
MKIVDVIGEK-AKEDFLR-a2-b2 RIIα Cβ 268 23 0 33.33 
DILLFKNLDQEQLSQVLDAMFER-IYKDGER-a6-b3 RIIα RIIα 137 279 0 33.32 
IVDVIGEKIYKDGER-GTYDILVTKDNQTR-a8-b9 RIIα RIIα 276 186 0.64 33.26 
LKQIEHTLNEKR-AKEDFLR-a2-b2 Cβ Cβ 83 23 0 33.21 
SNKDGGNQEVEIAR-VIHPKTDEQR-a3-b5 RIIα RIIα 314 118 0 33.18 
HKATEQYYAMKILDK-LKQIEHTLNEKR-a11-b2 Cβ Cβ 72 83 0.66 33.12 
TKSNKDGGNQEVEIAR-GQYFGELALVTNKPR-a5-b13 RIIα RIIα 314 341 0.79 33.05 
TKSNKDGGNQEVEIAR-IIVKNNAK-a2-b4 RIIα RIIα 311 239 0 32.91 
FGNLKNGVSDIKTHK-AKEDFLRK-a12-b2 Cβ Cβ 292 23 0.37 32.78 
VADAKGDSESEEDEDLEVPVPSR-NLLQVDLTKR-a5-b9 RIIα Cβ 71 279 0 32.74 
RNISHYEEQLVKMFGSSVDLGNLGQ-
TKSNKDGGNQEVEIAR-a12-b2 RIIα RIIα 387 311 0.65 32.55 
KVEAPFIPK-ILDKQK-a1-b4 Cβ Cβ 309 76 0 32.38 
KWENPPPSNAGLEDFER-AKEDFLR-a1-b2 Cβ Cβ 29 23 0.24 32.34 
KTLGTGSFGR-VMLVKHK-a1-b5 Cβ Cβ 47 61 0 32.16 
FPSHFSSDLKDLLR-NLLQVDLTKR-a10-b9 Cβ Cβ 266 279 0.81 32.16 
VVKLKQIEHTLNEK-ILDKQK-a3-b4 Cβ Cβ 81 76 0.95 32.11 
HKATEQYYAMK-KKTLGTGSFGR-a2-b1 Cβ Cβ 63 46 0.55 32.07 
ATEQYYAMKILDK-VMLVKHK-a9-b5 Cβ Cβ 72 61 0 31.86 
IVKADEHVIDQGDDGDNFYVIER-GTYDILVTKDNQTR-
a3-b9 RIIα RIIα 157 186 0.54 31.84 
QIEHTLNEKR-ILDKQK-a9-b4 Cβ Cβ 92 76 0.79 31.8 
RKMFESFIESVPLLK-IIVKNNAKK-a2-b4 RIIα RIIα 246 239 0 31.66 
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TKSNKDGGNQEVEIAR-GQYFGELALVTNKPR-a2-b13 RIIα RIIα 311 341 0 31.65 
GQYFGELALVTNKPR-SNKDGGNQEVEIAR-a13-b3 RIIα RIIα 341 314 0 31.54 
NGVSDIKTHK-KVEAPFIPK-a7-b1 Cβ Cβ 292 309 0 31.26 
FGNLKNGVSDIKTHK-NLLQVDLTKR-a5-b9 Cβ Cβ 285 279 0.79 31.19 
QSLGHPPPEPGPDRVADAKGDSESEEDEDLEVPVPSR-
GTYDILVTKDNQTR-a19-b9 RIIα RIIα 71 186 0.67 31.01 
TKSNKDGGNQEVEIAR-GTYDILVTKDNQTR-a2-b9 RIIα RIIα 311 186 0.77 30.84 
QIEHTLNEKR-AKEDFLR-a9-b2 Cβ Cβ 92 23 0 30.7 
LKQIEHTLNEKR-ILDKQKVVK-a11-b6 Cβ Cβ 92 78 0.81 30.53 
KVEAPFIPKFR-AKEDFLR-a9-b2 Cβ Cβ 317 23 0.58 30.17 
KTLGTGSFGR-VEAPFIPKFR-a1-b8 Cβ Cβ 47 317 0 30.16 
LKQIEHTLNEKR-IIVKNNAK-a2-b4 Cβ RIIα 83 239 0.58 30.08 
GTYDILVTKDNQTR-ILDKQKVVK-a9-b6 RIIα Cβ 186 78 0.93 29.97 
TKSNKDGGNQEVEIAR-NNAKKR-a2-b4 RIIα RIIα 311 243 0.52 29.59 
VADAKGDSESEEDEDLEVPVPSR-IVSGKVR-a5-b5 RIIα Cβ 71 254 0 29.55 
SNKDGGNQEVEIAR-MKIVDVIGEK-a3-b2 RIIα RIIα 314 268 0 29.5 
VIHPKTDEQR-ILDKQKVVK-a5-b4 RIIα Cβ 118 76 0 29.25 
IVDVIGEKIYKDGER-IIVKNNAK-a8-b4 RIIα RIIα 276 239 0 29.15 
MKIVDVIGEK-IIVKNNAK-a2-b4 RIIα RIIα 268 239 0 28.97 
LKQIEHTLNEKR-ILDKQKVVK-a11-b4 Cβ Cβ 92 76 0 28.66 
LEYSFKDNSNLYMVMEYVPGGEMFSHLR-
QIEHTLNEKR-a6-b9 Cβ Cβ 111 92 0.22 28.59 
ATEQYYAMKILDK-AKEDFLR-a9-b2 Cβ Cβ 72 23 0 28.58 
GTYDILVTKDNQTR-IIVKNNAK-a9-b4 RIIα RIIα 186 239 0.49 28 
VADAKGDSESEEDEDLEVPVPSR-KMFESFIESVPLLK-
a5-b1 RIIα RIIα 71 246 0 27.74 
SNKDGGNQEVEIAR-EFLAKAK-a3-b5 RIIα Cβ 314 21 0 27.72 
SNKDGGNQEVEIAR-IVSGKVR-a3-b5 RIIα Cβ 314 254 0 27.63 
VIHPKTDEQR-IVSGKVR-a5-b5 RIIα Cβ 118 254 0 27.54 
QSLGHPPPEPGPDRVADAKGDSESEEDEDLEVPVPSR-
NLLQVDLTKR-a19-b9 RIIα Cβ 71 279 0 27.5 
VADAKGDSESEEDEDLEVPVPSRFNR-
GTYDILVTKDNQTR-a5-b9 RIIα RIIα 71 186 0.46 27.31 
IVKADEHVIDQGDDGDNFYVIER-
VADAKGDSESEEDEDLEVPVPSR-a3-b5 RIIα RIIα 157 71 0.71 27.25 
NISHYEEQLVKMFGSSVDLGNLGQ-
KMFESFIESVPLLKSLEVSER-a11-b14 RIIα RIIα 387 259 0.46 27.15 
QIEHTLNEKR-IIVKNNAK-a9-b4 Cβ RIIα 92 239 0 26.99 
QSLGHPPPEPGPDRVADAKGDSESEEDEDLEVPVPSR-
MKIVDVIGEK-a19-b2 RIIα RIIα 71 268 0 26.92 
HKATEQYYAMK-ILDKQK-a2-b4 Cβ Cβ 63 76 0.7 26.86 
VADAKGDSESEEDEDLEVPVPSR-FPSHFSSDLKDLLR-
a5-b10 RIIα Cβ 71 266 0.88 26.68 
KMFESFIESVPLLK-IIVKNNAKK-a1-b8 RIIα RIIα 246 243 0 26.53 
VRFPSHFSSDLKDLLR-KVEAPFIPK-a12-b1 Cβ Cβ 266 309 0 26.51 
AKEDFLR-IVSGKVR-a2-b5 Cβ Cβ 23 254 0 26.47 
LKQIEHTLNEKR-NGVSDIKTHK-a11-b7 Cβ Cβ 92 292 0 26.44 
LKQIEHTLNEK-AKEDFLR-a2-b2 Cβ Cβ 83 23 0 26.43 
VADAKGDSESEEDEDLEVPVPSR-
VRFPSHFSSDLKDLLR-a5-b12 RIIα Cβ 71 266 0 26.3 
ATEQYYAMKILDK-LKQIEHTLNEKR-a9-b11 Cβ Cβ 72 92 0.34 26.27 
LEYSFKDNSNLYMVMEYVPGGEMFSHLR-
LKQIEHTLNEKR-a6-b11 Cβ Cβ 111 92 0 26.18 
NLLQVDLTKR-AKEDFLR-a9-b2 Cβ Cβ 279 23 0 26.16 
NLLQVDLTKRFGNLK-NGVSDIKTHK-a9-b7 Cβ Cβ 279 292 0 26.1 
IVKADEHVIDQGDDGDNFYVIER-IIVKNNAK-a3-b4 RIIα RIIα 157 239 0.2 25.73 
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VADAKGDSESEEDEDLEVPVPSR-MKIVDVIGEK-a5-b2 RIIα RIIα 71 268 0 25.15 
VMLVKHK-ILDKQK-a5-b4 Cβ Cβ 61 76 0 25.13 
DLKPENLLIDHQGYIQVTDFGFAKR-KVEAPFIPK-a24-b1 Cβ Cβ 189 309 0.37 24.94 
IVKADEHVIDQGDDGDNFYVIER-AKEDFLR-a3-b2 RIIα Cβ 157 23 0 24.77 
HKATEQYYAMKILDK-QKVVKLK-a11-b2 Cβ Cβ 72 78 0.95 24.56 
KMFESFIESVPLLK-RIIVKNNAK-a1-b5 RIIα RIIα 246 239 0.86 24.36 
GTYDILVTKDNQTR-LKQIEHTLNEKR-a9-b11 RIIα Cβ 186 92 0.46 23.96 
GTYDILVTKDNQTR-LKQIEHTLNEKR-a9-b2 RIIα Cβ 186 83 0.52 23.87 
LEYSFKDNSNLYMVMEYVPGGEMFSHLR-
LKQIEHTLNEKR-a6-b2 Cβ Cβ 111 83 0.17 23.64 
KWENPPPSNAGLEDFER-KVEAPFIPK-a1-b1 Cβ Cβ 29 309 0 23.61 
DLKPENLLIDHQGYIQVTDFGFAKR-AKEDFLRK-a24-b2 Cβ Cβ 189 23 0 23.48 
RKMFESFIESVPLLK-ILDKQK-a2-b4 RIIα Cβ 246 76 0 23.14 
VADAKGDSESEEDEDLEVPVPSRFNR-
VRFPSHFSSDLKDLLR-a5-b12 RIIα Cβ 71 266 0.48 23.09 
NISHYEEQLVKMFGSSVDLGNLGQ-
VADAKGDSESEEDEDLEVPVPSR-a11-b5 RIIα RIIα 387 71 0 22.63 
VADAKGDSESEEDEDLEVPVPSR-
SNKDGGNQEVEIAR-a5-b3 RIIα RIIα 71 314 0 22.09 
ATEQYYAMKILDKQK-LKQIEHTLNEKR-a9-b2 Cβ Cβ 72 83 0.7 21.98 
ILDKQK-NNAKKR-a4-b4 Cβ RIIα 76 243 0.74 21.72 
VADAKGDSESEEDEDLEVPVPSR-KVEAPFIPKFR-a5-
b9 RIIα Cβ 71 317 0 21.64 
QSLGHPPPEPGPDRVADAKGDSESEEDEDLEVPVPSR-
IVSGKVR-a19-b5 RIIα Cβ 71 254 0.21 21.59 
KMFESFIESVPLLKSLEVSER-RIIVKNNAK-a1-b5 RIIα RIIα 246 239 0.32 21.46 
LKQIEHTLNEKR-AKEDFLR-a11-b2 Cβ Cβ 92 23 0 21.31 
VADAKGDSESEEDEDLEVPVPSR-IVDVIGEKIYKDGER-
a5-b8 RIIα RIIα 71 276 0 21.24 
DLKPENLLIDHQGYIQVTDFGFAKR-KKTLGTGSFGR-
a24-b2 Cβ Cβ 189 47 0 21.22 
LKQIEHTLNEK-ILDKQKVVK-a2-b4 Cβ Cβ 83 76 0.95 21.12 
KWENPPPSNAGLEDFER-NGVSDIKTHK-a1-b7 Cβ Cβ 29 292 0.27 20.79 
IVKADEHVIDQGDDGDNFYVIER-IYKDGER-a3-b3 RIIα RIIα 157 279 0.38 20.34 
DLKPENLLIDHQGYIQVTDFGFAKR-KKTLGTGSFGR-
a24-b1 Cβ Cβ 189 46 0.23 20.09 
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Table S5. Quantitative XL-MS comparison of crosslinking site intensity ± AKAP18α. 
The table lists the relative change in crosslinking between different lysine pairs within 
RIIβ-Cβ upon inclusion of AKAP18α. Lysine pairs are listed starting with the link that 
was most reduced by inclusion of AKAP18α. Changes in abundance are expressed as 
log2 (abundance with AKAP18α/abundance without AKAP18α). p value indicates the 
regression between the two conditions. 
 
Protein A Protein B Position A Position B 
log2-ratio 
(+18α/-18α) p value 
RIIβ RIIβ 285 324 -2.428 1.32E-09 
Cβ RIIβ 266 46 -1.536 0.0025818 
RIIβ RIIβ 263 46 -1.37 1.58E-05 
RIIβ RIIβ 285 46 -1.237 1.30E-06 
RIIβ RIIβ 357 46 -1.113 0.000116665 
Cβ RIIβ 192 263 -1.096 0.0120618 
RIIβ RIIβ 174 46 -0.655 0.00032057 
Cβ Cβ 192 23 -0.652 1.65E-05 
Cβ RIIβ 81 285 -0.646 0.00159942 
RIIβ RIIβ 326 357 -0.608 0.052444 
RIIβ RIIβ 256 263 -0.547 0.062685 
RIIβ RIIβ 256 285 -0.433 0.00022393 
RIIβ RIIβ 260 263 -0.426 0.042998 
RIIβ RIIβ 260 285 -0.408 0.035763 
RIIβ RIIβ 135 256 -0.39 0.035824 
Cβ Cβ 254 279 -0.362 0.021884 
Cβ Cβ 23 309 -0.332 0.0020576 
RIIβ RIIβ 324 326 -0.316 0.23174 
Cβ RIIβ 254 174 -0.285 0.0066222 
Cβ Cβ 47 61 -0.201 0.35244 
RIIβ RIIβ 174 256 -0.167 0.40362 
RIIβ RIIβ 324 328 -0.145 0.43816 
Cβ Cβ 23 92 -0.033 0.69412 
Cβ Cβ 76 81 -0.029 0.92618 
Cβ Cβ 292 309 0.025 0.86738 
Cβ Cβ 317 47 0.041 0.5802 
Cβ Cβ 292 29 0.068 0.76764 
RIIβ RIIβ 135 285 0.076 0.67778 
Cβ Cβ 317 46 0.105 0.173977 
Cβ Cβ 81 92 0.176 0.130277 
Cβ Cβ 23 292 0.229 0.15416 
Cβ Cβ 23 61 0.251 0.37134 
Cβ Cβ 292 92 0.262 0.37174 
Cβ Cβ 76 92 0.328 0.00040339 
Cβ Cβ 78 83 0.336 0.044683 
RIIβ RIIβ 328 357 0.336 0.000160641 
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RIIβ RIIβ 135 174 0.36 0.00058064 
Cβ Cβ 72 92 0.488 0.084118 
Cβ Cβ 29 76 0.558 0.123624 
Cβ Cβ 61 72 0.62 0.048564 
Cβ Cβ 72 81 0.699 0.0199013 
Cβ Cβ 76 83 0.715 4.07E-06 
Cβ Cβ 23 83 0.939 0.00022252 
Cβ Cβ 72 83 0.971 0.011418 
Cβ Cβ 16 292 1.086 1.26E-06 
 
